Healthcare-Acquired Infections

Answer Card

Definition: Healthcare-acquired infections (HAIs), also known as nosocomial infections, are infections acquired during the process of receiving healthcare that were not present at the time of admission.

ICU Impact: HAIs affect 10-30% of ICU patients, associated with 2-3-fold increased mortality, prolonged ICU stay (median +8 days), and excess healthcare costs (AUD 18,000-50,000 per case).

Priority Areas: Central line-associated bloodstream infections (CLABSI), catheter-associated urinary tract infections (CAUTI), ventilator-associated pneumonia (VAP), surgical site infections (SSI), and Clostridioides difficile infection (CDI).

Prevention Strategy: Multimodal bundle implementation, surveillance, and antimicrobial stewardship. ICU patients have highest HAI rates due to invasive devices, immunosuppression, and antimicrobial pressure.

---

Clinical Overview

Healthcare-acquired infections (HAIs) represent a major patient safety challenge in intensive care, contributing significantly to morbidity, mortality, and healthcare costs. The World Health Organization estimates that at any point in time, 7% of patients in developed and 15% in developing countries will acquire at least one HAI. In intensive care units (ICUs), infection rates are 5-10 times higher than in general wards, with ventilator-associated pneumonia being the most common ICU-acquired infection, followed by catheter-associated urinary tract infections and bloodstream infections.

The economic burden of HAIs is substantial, with each infection adding approximately AUD 18,000-50,000 to healthcare costs and extending hospital stay by 5-15 days. Beyond the direct clinical and economic impact, HAIs contribute to antimicrobial resistance through selective pressure, creating a vicious cycle that threatens the effectiveness of existing antibiotics. The emergence of multidrug-resistant organisms (MDROs) such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant Enterobacterales (CRE), and extensively drug-resistant Pseudomonas aeruginosa presents particular challenges for ICU clinicians.

ICU patients represent the highest-risk population for HAIs due to multiple factors: impaired host defenses from critical illness, invasive devices bypassing natural barriers, frequent exposure to antimicrobials, and prolonged length of stay. The combination of these factors creates an environment where pathogens can easily colonise and cause infection, often with organisms that are resistant to first-line agents. Understanding the epidemiology, prevention strategies, and management of HAIs is therefore essential for all intensivists.

---

Epidemiology

The global epidemiology of HAIs varies by region, hospital type, and patient population. Large point prevalence surveys conducted by the World Health Organization reveal that ICU infection rates range from 15-30% in high-income countries and 30-60% in low- and middle-income countries. The European Centre for Disease Prevention and Control (ECDC) reports an ICU-acquired infection prevalence of 7.1% across European ICUs, with device-associated infections accounting for the majority.

In Australia, the Australian Commission on Safety and Quality in Health Care monitors HAI rates through the National Safety and Quality Health Service (NSQHS) Standards. Australian ICU CLABSI rates have decreased by 46% between 2012-2018 following bundle implementation, from 2.0 to 1.1 per 1000 central line-days. Similarly, CAUTI rates have shown modest improvement, while VAP remains the most common ICU-acquired infection with rates varying from 1-5 per 1000 ventilator-days depending on diagnostic criteria.

Device utilisation ratios directly correlate with infection risk. Central lines, urinary catheters, and mechanical ventilation each increase infection risk by approximately 5-7 times compared with non-invasively managed patients. The risk is not linear—each additional day of device use confers cumulative risk, with central line-associated bloodstream infection risk estimated at 2.7 per 1000 line-days, CAUTI at 3-5 per 1000 catheter-days, and VAP at 3-16 per 1000 ventilator-days depending on patient population.

ICU patients with specific conditions have higher HAI rates: immunosuppression (transplant recipients, chemotherapy), severe sepsis, traumatic brain injury, prolonged mechanical ventilation (greater than 7 days), and those receiving parenteral nutrition. Indigenous Australians and Māori patients have higher rates of HAIs, reflecting underlying health disparities, higher comorbidity burden, and barriers to accessing timely healthcare including delayed presentation and advanced disease at ICU admission.

---

Pathophysiology

The pathogenesis of HAIs involves complex interactions between host factors, microbial virulence, and environmental exposures. In ICU patients, impaired host defences are paramount: disrupted skin and mucosal barriers from devices, neutrophil dysfunction from critical illness, immunosuppression from medications or disease states, and dysbiosis of normal flora from broad-spectrum antibiotics. These factors create opportunities for pathogens to cause infection that would be prevented in immunocompetent individuals.

Microbial colonisation precedes infection in the majority of HAIs. For catheter-associated infections, organisms migrate along the external surface from the insertion site, or via the lumen from contaminated hubs. VAP pathogenesis involves microaspiration of oropharyngeal contents colonised with pathogenic bacteria, with the endotracheal tube providing a direct conduit for bacterial entry to the lower respiratory tract. Surgical site infections occur from contamination during surgery, haematogenous seeding, or local spread from adjacent infected sites.

Biofilm formation on device surfaces plays a critical role in device-associated infections. Bacteria adhere to device surfaces and produce an extracellular polymeric substance that protects from host immune defences and antimicrobial agents. Biofilms can harbour multiple bacterial species and facilitate horizontal gene transfer of resistance determinants. Once established, biofilm-associated infections typically require device removal for cure, as antibiotics penetrate poorly into the biofilm matrix.

Antimicrobial pressure in ICUs selects for resistant organisms through both selection of resistant mutants and horizontal transfer of resistance genes. Broad-spectrum antibiotic use disrupts normal flora, allowing colonisation and overgrowth of resistant organisms. This selective pressure is particularly intense in ICUs where up to 70% of patients receive antibiotics at any given time. The resulting MDROs then cause infections that are difficult to treat, further perpetuating antimicrobial use and resistance—a cycle that is difficult to break without comprehensive stewardship and infection control programs.

---

CLABSI: Central Line-Associated Bloodstream Infection

Definition and Diagnosis

Central line-associated bloodstream infection (CLABSI) is defined as a laboratory-confirmed bloodstream infection where an eligible central line was in place for greater than 48 hours on the date of event or the day before, and the line was in place on the date of event or the day before. The diagnosis requires either a recognised pathogen cultured from one or more blood cultures that is not related to infection at another site, or one of the following: common skin commensal cultured from two or more blood cultures, common skin commensal from one blood culture with clinical signs of infection, or common skin commensal from one blood culture with positive line tip culture.

The CDC surveillance definition differs from clinical catheter-related bloodstream infection (CRBSI) which requires catheter tip culture demonstrating same organism with quantitative colony count ratio greater than 3:1 (catheter to peripheral blood) or differential time to positivity greater than 2 hours (catheter vs peripheral). This surveillance definition is used for benchmarking and quality improvement, while CRBSI diagnosis guides individual patient management. In clinical practice, the decision to remove a central line should be based on clinical suspicion of line infection rather than awaiting culture confirmation in unstable patients.

Risk Factors

Major risk factors for CLABSI include prolonged catheter duration (greater than 7 days), femoral insertion site (2-5× higher infection risk compared with subclavian), suboptimal insertion technique (failure to maintain full barrier precautions), frequent line manipulations (blood sampling, medication administration), neutropenia, total parenteral nutrition, and emergent insertion without optimal preparation. Multilumen catheters have slightly higher infection rates, though this may reflect higher utilisation in sicker patients. Patient factors including diabetes, immunosuppression, and severe malnutrition further increase risk.

Prevention Bundle

The Keystone ICU CLABSI bundle, first implemented in Michigan hospitals and published in the New England Journal of Medicine in 2006, demonstrated a 66% reduction in CLABSI rates from 2.7 to 0.9 per 1000 catheter-days. This success has been replicated worldwide, including Australian ICUs. The five core bundle components are:

1. Hand hygiene: Perform hand hygiene before and after palpating catheter insertion sites, as well as before and after inserting, replacing, accessing, repairing, or dressing catheters. Alcohol-based hand rubs are preferred for routine hand hygiene unless hands are visibly soiled, in which case soap and water should be used.

2. Maximal barrier precautions: Use maximal sterile barrier precautions during central line insertion, including cap, mask, sterile gown, sterile gloves, and a large sterile patient drape. Full barrier precautions reduce CLABSI by 50-60% compared with standard precautions. The entire insertion team (operator and assistant) should wear full barriers.

3. Chlorhexidine skin antisepsis: Clean skin with chlorhexidine gluconate 0.5% in 70% alcohol (≥0.5% chlorhexidine) before catheter insertion and during dressing changes. Chlorhexidine is superior to povidone-iodine for catheter insertion site antisepsis, with meta-analyses showing 40-50% lower infection rates. Allow chlorhexidine to dry completely before proceeding with insertion (typically 30-60 seconds). For patients with chlorhexidine allergy, povidone-iodine may be used as an alternative.

4. Optimal catheter site selection: Avoid the femoral vein for catheter insertion in adult patients due to higher infection risk. The subclavian site has the lowest infection rate, followed by internal jugular, then femoral. However, site selection must balance infection risk against mechanical complications—subclavian insertion has higher risk of pneumothorax, while internal jugular is associated with higher infection rates but easier insertion in emergencies.

5. Daily review for catheter necessity: Remove unnecessary catheters promptly. Each additional day of catheter use increases infection risk, and many catheters remain in place without clear ongoing indication. Daily multi-disciplinary rounds should include catheter review, with removal of any line not actively required for patient care.

Additional evidence-based practices include using antimicrobial-impregnated catheters (minocycline-rifampin or chlorhexidine-silver sulfadiazine) in patients with CLABSI rates above institutional benchmarks despite bundle implementation, using antiseptic- or antibiotic-impregnated dressings, and avoiding routine catheter replacement at scheduled intervals. Catheter replacement on clinical indication only is recommended.

Catheter Maintenance

Catheter maintenance practices are as important as insertion techniques. Catheter hubs and needleless connectors should be scrubbed with an appropriate antiseptic (chlorhexidine, povidone-iodine, or 70% alcohol) before accessing. This simple practice, often overlooked, reduces catheter colonisation and subsequent infection. Dressing changes should be performed using aseptic technique, with replacement every 5-7 days for gauze dressings and at least every 7 days for transparent semipermeable membrane dressings, or sooner if the dressing becomes soiled, loose, or damp.

Systemic antimicrobial prophylaxis is not recommended for CLABSI prevention. Similarly, routine catheter culture and replacement at scheduled intervals do not reduce infection rates and are discouraged. Antibiotic lock solutions may be considered in selected high-risk patients with long-term catheters, though evidence is limited to specific populations such as haemodialysis patients with recurrent infections.

Management

Management of suspected CLABSI includes obtaining blood cultures (preferably one set percutaneously and one set through each central line lumen) before initiating antibiotics. Empiric antibiotic therapy should cover gram-positive organisms including MRSA (vancomycin) and gram-negative organisms (pseudomonal coverage) based on local antimicrobial resistance patterns. Source control with catheter removal is recommended for most patients with CLABSI, particularly if the patient is unstable, infection is caused by Staphylococcus aureus or Pseudomonas aeruginosa, or infection persists despite 72 hours of appropriate antibiotics.

For catheters retained due to limited access (e.g., haemodialysis catheters), antibiotic lock therapy may be used in conjunction with systemic antibiotics. Catheter tip culture should be sent to confirm catheter as the source. Duration of therapy is typically 7-14 days depending on the pathogen and clinical response, with longer courses (4-6 weeks) for complicated infections involving endocarditis, septic thrombophlebitis, or osteomyelitis.

---

CAUTI: Catheter-Associated Urinary Tract Infection

Definition and Diagnosis

Catheter-associated urinary tract infection (CAUTI) is defined as a urinary tract infection where an indwelling urinary catheter was in place for greater than 2 days on the date of event, or the day before. The surveillance definition requires either a urine culture with greater than 10^5 CFU/mL of a recognised pathogen, or greater than 10^5 CFU/mL of a uropathogen with signs or symptoms compatible with UTI (fever, suprapubic tenderness, costovertebral angle pain, urinary urgency, frequency, or dysuria). For patients without catheters, the same definition applies without the device criterion.

Clinical diagnosis in ICU patients is complicated by frequent non-specific signs of infection and inability to report urinary symptoms. Pyuria and bacteriuria alone are common in catheterised patients and do not constitute infection requiring treatment. Treatment is indicated only when symptomatic infection is present, as colonisation without treatment does not progress to symptomatic infection or bacteraemia in the majority of cases.

Risk Factors

Risk factors for CAUTI include prolonged catheter duration (greater than 7 days), female gender, older age, diabetes mellitus, lack of systemic antibiotics, inappropriate catheter care, bacterial colonisation of the drainage bag, and breaches in the closed drainage system. Higher catheter insertion volumes (greater than 400 mL) and use of catheters for monitoring urine output without clear indication contribute to unnecessary duration and increased infection risk.

Prevention Strategies

The cornerstone of CAUTI prevention is avoiding unnecessary catheterisation. Indications for urinary catheter placement in ICU include acute urinary retention or bladder outlet obstruction, need for accurate hourly urine output monitoring in critically ill or haemodynamically unstable patients, prolonged immobilisation or need for surgical position that prevents voiding, requirement for bladder irrigation, perioperative use for selected procedures, and assistance in healing perineal and sacral wounds in incontinent patients.

Contraindications to catheterisation include lack of indication—catheters should not be placed for nursing convenience or without clear clinical indication. Alternatives to indwelling catheters include external collection devices (condom catheters) for men, intermittent catheterisation where appropriate, and bladder scanners to assess post-void residual volume before catheter insertion in selected patients.

The CAUTI prevention bundle includes:

1. Appropriate catheter use: Avoid unnecessary catheter insertion. Use catheters only for appropriate indications and document indication in medical record. Daily review of necessity with prompt removal when no longer indicated is essential.

2. Aseptic insertion and maintenance: Use sterile equipment and sterile technique for catheter insertion. Maintain a closed drainage system—never disconnect the tubing. Keep the catheter and collection bag below the level of the bladder to prevent backflow of urine.

3. Secure catheter properly: Secure the catheter to prevent movement and urethral traction, which can cause inflammation and infection. Proper fixation also reduces tension on the bladder neck and minimises tissue trauma.

4. Daily catheter care: Perform daily meatal care with water and mild soap. Routine antimicrobial prophylaxis or irrigation is not recommended. Routine catheter replacement is not indicated—change only if clinically indicated.

5. Education: Ensure all healthcare workers caring for catheterised patients receive education on proper catheter insertion techniques, maintenance practices, and indications for removal. This includes nursing staff, medical staff, and allied health.

Additional evidence-based practices include using catheters with antimicrobial impregnation or silver alloy coating for patients with recurrent CAUTI, ensuring adequate fluid intake to promote urinary flow, and maintaining appropriate catheter size (typically 16-18 Fr in adults) to minimise urethral trauma.

Management

Management of symptomatic CAUTI includes obtaining urine culture before initiating antibiotics and removing or replacing the indwelling catheter if possible. Antibiotic selection should be based on local antimicrobial susceptibility patterns, with adjustment once culture results are available. Duration of therapy is typically 7-14 days for uncomplicated infection, with longer courses reserved for complicated infections involving pyelonephritis, prostatitis, or systemic sepsis.

Catheter replacement may be considered when managing infection in a retained catheter, as the biofilm on the catheter surface can harbour organisms despite systemic antibiotics. For patients with recurrent CAUTI, evaluation for underlying abnormalities (urethral stricture, bladder stones, anatomical abnormalities) should be considered.

---

VAP: Ventilator-Associated Pneumonia

Definition and Diagnosis

Ventilator-associated pneumonia (VAP) is defined as pneumonia arising more than 48 hours after endotracheal intubation. Diagnosis remains challenging due to non-specific clinical signs and the limitations of available diagnostic tests. Clinical criteria include new or progressive infiltrate on chest radiograph plus at least two of: fever greater than 38°C or below 36°C, leukocytosis greater than 12,000/mm³ or leukopenia below 4,000/mm³, and purulent respiratory secretions. These criteria are sensitive but non-specific, with positive predictive value as low as 30-40% in some studies.

More specific diagnostic strategies include quantitative cultures from bronchoalveolar lavage (BAL) with a threshold of greater than 10^4 CFU/mL, or protected specimen brush (PSB) with greater than 10^3 CFU/mL. Invasive diagnosis with bronchoscopy-guided sampling is preferred over non-invasive tracheal aspiration, as the latter can sample colonised upper airway organisms rather than lower respiratory tract pathogens. However, invasive techniques require expertise and are not universally available. The most pragmatic approach is clinical suspicion combined with quantitative cultures from either invasive or non-invasive methods, with antibiotic stewardship based on culture results.

Risk Factors

Risk factors for VAP include prolonged mechanical ventilation (greater than 5 days), supine positioning, enteral feeding, prior antibiotic exposure, chronic lung disease, head trauma, and aspiration. The endotracheal tube itself facilitates VAP by allowing leakage of secretions around the cuff, pooling of secretions above the cuff, providing a surface for biofilm formation, and preventing effective cough and mucociliary clearance. Host factors including immunosuppression, malnutrition, and age greater than 65 years further increase risk.

Prevention Bundle

The Institute for Healthcare Improvement (IHI) VAP bundle includes five evidence-based components:

1. Elevation of the head of the bed: Maintain head of bed elevation at 30-45 degrees unless contraindicated (e.g., spinal instability, haemodynamic instability). Meta-analyses show a 30-40% reduction in VAP risk with semi-recumbent positioning. However, studies of continuous backrest angle monitoring reveal that actual head-of-bed elevation often falls below target, with average angles of 20-25 degrees despite orders for 30-45 degrees.

2. Daily sedation interruption and assessment of readiness to wean: Perform a daily sedation vacation and spontaneous breathing trial. Sedation interruption reduces duration of mechanical ventilation by approximately 2-3 days and reduces ICU length of stay. Combining daily sedation interruption with spontaneous breathing trials (SBT) reduces time on ventilation and decreases VAP incidence. Protocols targeting both sedation minimisation and ventilator weaning are more effective than either strategy alone.

3. Peptic ulcer disease prophylaxis: Use stress ulcer prophylaxis (PUD prophylaxis) in appropriate patients. While early concerns existed that gastric acid suppression might increase VAP risk by facilitating gastric bacterial overgrowth, subsequent studies have not demonstrated increased VAP with histamine-2 receptor antagonists or proton pump inhibitors. The benefit of stress ulcer prophylaxis in high-risk patients outweighs theoretical VAP risk.

4. Deep vein thrombosis prophylaxis: Use appropriate venous thromboembolism (VTE) prophylaxis. While DVT prophylaxis is not directly related to VAP prevention, it is included in the VAP bundle as a core ICU care quality measure. Mechanical VTE prophylaxis (sequential compression devices) or chemical prophylaxis (low molecular weight heparin) should be used unless contraindicated.

5. Daily oral care with chlorhexidine: Provide oral care with chlorhexidine gluconate 0.12% or 0.2% solution every 2-4 hours for intubated patients. Oral decontamination reduces oropharyngeal colonisation with pathogenic bacteria and subsequent microaspiration. Meta-analyses show a 30-40% reduction in VAP with chlorhexidine oral care, though studies vary in concentration, frequency, and method of application.

Additional evidence-based VAP prevention strategies include:

• Subglottic secretion drainage: Use endotracheal tubes with dorsal lumen for continuous or intermittent subglottic secretion drainage. Secretions pool above the cuff and can be aspirated around the cuff into the lower respiratory tract. Drainage reduces VAP by 30-50%, particularly in patients ventilated greater than 48-72 hours.

• Early mobilisation: Implement early mobilisation protocols for mechanically ventilated patients when clinically feasible. Early activity reduces diaphragm dysfunction, improves secretion clearance, and reduces VAP risk. Safety is demonstrated when protocols are individualised and physiotherapy involvement is assured.

• Cuff pressure monitoring: Maintain endotracheal tube cuff pressure at 20-30 cmH2O to prevent leakage of secretions while minimising tracheal injury. Automated continuous cuff pressure monitoring may be superior to intermittent manual checks.

• Selective digestive decontamination (SDD): Use topical antibiotics (e.g., polymyxin, tobramycin, amphotericin B) applied to oropharynx and stomach, combined with systemic antibiotics for the first few days of ventilation. SDD dramatically reduces VAP and mortality in European trials, but concerns about antimicrobial resistance have limited adoption in many countries including Australia. Selective oropharyngeal decontamination (SOD) without systemic antibiotics shows similar VAP reduction with less antimicrobial pressure.

• Avoidance of routine circuit changes: Ventilator circuits should be changed only when visibly soiled or malfunctioning, not on a scheduled basis. Routine changes do not reduce VAP and may increase contamination risk. Similarly, in-line suction catheters should be changed according to manufacturer recommendations rather than on fixed schedules.

Sedation Management

Appropriate sedation management is critical for VAP prevention. Continuous sedation infusions without daily interruption prolong mechanical ventilation and increase VAP risk. Protocolised sedation with targeted sedation goals (e.g., Richmond Agitation-Sedation Scale -1 to +2) and daily sedation interruption reduces duration of ventilation by 2-3 days and VAP incidence by 20-30%.

When daily sedation interruption is performed, the sedative infusion is stopped and patients are assessed for readiness to awaken. Patients who awaken can undergo spontaneous breathing trials to assess readiness for extubation. If patients become agitated or uncomfortable during sedation interruption, a reduced dose of sedative can be administered with the goal of maintaining patient comfort while allowing daily assessment.

Benzodiazepines (midazolam, lorazepam) are associated with prolonged ventilation and higher delirium rates compared with propofol or dexmedetomidine. Dexmedetomidine, an alpha-2 agonist, produces sedation with minimal respiratory depression and may reduce delirium incidence and facilitate earlier extubation. However, dexmedetomidine is more expensive and may not be suitable for all patients.

Management

Empiric antibiotic therapy for suspected VAP should cover both gram-positive organisms (including MRSA) and gram-negative organisms (including Pseudomonas aeruginosa and other multidrug-resistant organisms). Local antimicrobial resistance patterns and individual patient risk factors for MDROs (prior hospitalisation, prior antibiotic use, known colonisation) should guide empiric therapy choices.

Empiric therapy typically includes vancomycin (or linezolid) for MRSA coverage plus an antipseudomonal beta-lactam (piperacillin-tazobactam, cefepime, meropenem) or aztreonam if beta-lactam allergy. Double antipseudomonal coverage (two agents with pseudomonal activity) may be considered in patients with high risk for MDROs, though evidence for mortality benefit is lacking.

Antibiotic de-escalation based on culture results and clinical response is essential to minimise antimicrobial pressure and resistance. Duration of therapy should be 7-8 days for uncomplicated VAP, based on multiple RCTs showing no benefit from longer courses (14-21 days). Shorter courses (5-7 days) may be appropriate for patients with rapid clinical response and documented susceptible organisms.

---

SSI: Surgical Site Infection

Definition and Classification

Surgical site infection (SSI) is defined as infection occurring within 30 days after operation (or within 1 year if an implant is in place) involving the skin, subcutaneous tissue, or deep soft tissues at the operative site. The CDC classification system divides SSIs into:

• Superficial incisional SSI: Involving only skin or subcutaneous tissue at the incision site, with at least one of: purulent drainage, positive culture from fluid/tissue, signs of inflammation (pain, redness, swelling), or deliberate opening by surgeon.
• Deep incisional SSI: Involving deep soft tissues (fascia, muscle) of the incision, with purulent drainage, spontaneous dehiscence, or positive culture.
• Organ/space SSI: Involving any part of the anatomy other than the incision that was opened or manipulated during surgery, with purulent drainage from a drain, positive culture, or organ-space abscess.

Surgical wounds are classified according to the degree of microbial contamination:

• Clean: No inflammation, no break in technique, respiratory, alimentary, genital, or urinary tract not entered, no infection. Infection rate below 2%.
• Clean-contaminated: Respiratory, alimentary, genital, or urinary tract entered under controlled conditions without unusual contamination. Infection rate 3-4%.
• Contaminated: Open, fresh, accidental wound; major break in sterile technique; gross spillage from gastrointestinal tract; incision encountering acute inflammation without pus. Infection rate 6-9%.
• Dirty/infected: Old traumatic wound with devitalised tissue; clinical infection; perforated viscus; traumatic wound with retained devitalised tissue. Infection rate 13-20%.

Risk Factors

Patient-related risk factors for SSI include diabetes mellitus (particularly poor glycaemic control), obesity (BMI greater than 30), smoking, malnutrition (albumin below 35 g/L), immunosuppression (corticosteroids, chemotherapy), advanced age (greater than 65 years), and preoperative colonisation with pathogenic organisms (particularly MRSA). Diabetes increases SSI risk by 2-3 times, with HbA1c greater than 7-8% associated with higher infection rates even when intraoperative glucose is well-controlled.

Procedure-related risk factors include emergency surgery, prolonged operative time (greater than 2-3 hours), contaminated or dirty wound classification, inappropriate antibiotic prophylaxis (wrong agent, wrong timing, prolonged duration), poor tissue handling, excessive electrocautery use, and hypothermia. Perioperative transfusion also increases SSI risk, likely through immunomodulation effects of allogeneic blood products.

Prevention: Antibiotic Prophylaxis

Preoperative antibiotic prophylaxis is the single most effective measure for preventing SSI in clean and clean-contaminated procedures. Evidence-based guidelines from the CDC, WHO, and Surgical Infection Society provide detailed recommendations:

Timing: Administer prophylactic antibiotic within 60 minutes before incision (or 120 minutes for vancomycin or fluoroquinolones due to longer infusion time). This timing ensures peak tissue concentrations at the time of initial bacterial contamination. Administration greater than 2 hours preoperatively or after incision is ineffective and increases resistance risk.

Agent selection: Select antibiotic based on surgical procedure and most common pathogens. First-generation cephalosporins (cefazolin) are appropriate for most procedures. For cardiac surgery, prosthetic joint implantation, and other procedures where staphylococcal infections are catastrophic, cefazolin is preferred, with vancomycin added in facilities with high MRSA prevalence. For colorectal surgery, agents covering both aerobic and anaerobic flora are used (e.g., cefazolin plus metronidazole, or ertapenem). Beta-lactam allergic patients receive alternatives such as clindamycin, vancomycin, or aztreonam depending on procedure and allergy severity.

Dosing: Use weight-based dosing. Cefazolin 2g IV for patients below 120 kg, 3g IV for patients ≥120 kg. Vancomycin 15 mg/kg IV (maximum 2g). Metronidazole 500 mg IV. Obese patients (greater than 120 kg) require higher doses to achieve adequate tissue concentrations, as standard doses result in subtherapeutic levels.

Redosing: Redose intraoperatively if procedure duration exceeds two half-lives of the antibiotic or if there is substantial blood loss (greater than 1500 mL). For cefazolin (half-life ~2 hours), redose every 4 hours for long procedures. For vancomycin (half-life ~4-6 hours), redose if procedure exceeds 6 hours. Additional dosing may be required for patients undergoing cardiopulmonary bypass, which alters antibiotic pharmacokinetics.

Duration: Discontinue prophylactic antibiotics within 24 hours after surgery. For clean procedures, a single preoperative dose is sufficient. For clean-contaminated procedures, one additional postoperative dose (total 24 hours) is appropriate. There is no evidence that continuing antibiotics beyond 24 hours reduces SSI risk in clean and clean-contaminated cases. Prolonged prophylaxis increases antimicrobial resistance, Clostridioides difficile infection, and drug toxicity without additional benefit.

Prevention: Other Strategies

Glucose control: Maintain perioperative blood glucose below 200 mg/dL (11.1 mmol/L) for both diabetic and non-diabetic patients. Hyperglycaemia impairs immune function and increases infection risk. While strict glucose control (80-110 mg/dL) is harmful due to hypoglycaemia, moderate control (below 200 mg/dL) reduces SSI without increasing risk. Preoperative screening with HbA1c (greater than 6.5-7%) identifies undiagnosed diabetes and allows optimisation before elective surgery.

Normothermia: Maintain core body temperature greater than 36°C in surgical patients. Hypothermia impairs neutrophil function and reduces tissue oxygenation, increasing infection risk. Perioperative warming (forced-air warming blankets, warmed intravenous fluids, increased ambient temperature) reduces SSI risk by 30-50%, particularly for colorectal and other abdominal procedures.

Oxygenation: Administer increased inspired oxygen concentration (60-80%) intraoperatively and for 2-6 hours postoperatively for patients undergoing general anaesthesia with endotracheal intubation. Higher FiO2 increases tissue oxygen tension, enhancing neutrophil oxidative killing. Meta-analyses show a 20-30% reduction in SSI with increased perioperative oxygen, particularly for colorectal surgery.

Skin preparation: Use appropriate antiseptic for surgical site preparation. Alcohol-based chlorhexidine gluconate solutions are superior to aqueous povidone-iodine for most procedures. For patients with chlorhexidine allergy, iodophor preparations are appropriate. Hair removal is not routinely recommended; if hair must be removed, use clippers rather than razors to avoid microabrasions that facilitate bacterial entry.

Antibiotic sutures: Consider use of antimicrobial sutures (e.g., triclosan-coated polyglactin 910) for high-risk procedures. Meta-analyses show modest reduction in SSI (10-20% relative risk reduction) with coated sutures, though evidence quality is moderate. Cost-effectiveness varies by setting and procedure.

Bowel preparation: For colorectal surgery, combined mechanical bowel preparation plus oral antibiotics (e.g., neomycin, erythromycin, metronidazole) administered the day before surgery reduces SSI rates by 50-70% compared with mechanical preparation alone. However, practice patterns vary, and mechanical preparation alone may be appropriate for selected patients.

Management

Management of SSI includes wound opening and drainage for superficial infections, culture of wound fluid, and empiric antibiotics for deep or organ-space infections. Antibiotic selection should cover typical pathogens (skin flora for superficial infections, enteric flora for abdominal procedures) and be tailored based on culture results. Duration is typically 5-14 days depending on infection severity and clinical response.

For prosthetic device infections (joint replacements, cardiac devices, vascular grafts), management often requires prosthesis removal, prolonged antibiotic therapy (6-8 weeks), and staged reimplantation when possible. Consultation with infectious diseases and surgical specialists is recommended for complex cases.

---

Clostridioides difficile Infection

Definition and Diagnosis

Clostridioides difficile infection (CDI, formerly Clostridium difficile) ranges from asymptomatic colonisation to life-threatening pseudomembranous colitis and toxic megacolon. Clinical diagnosis requires presence of diarrhoea (≥3 unformed stools in 24 hours) and either a positive stool test for toxigenic C. difficile or colonoscopic/histopathologic findings of pseudomembranous colitis.

Diagnostic approaches include stool nucleic acid amplification tests (NAAT) for toxin genes (high sensitivity, detects both infection and colonisation), glutamate dehydrogenase (GDH) antigen testing (high sensitivity, detects both toxigenic and non-toxigenic strains), and stool toxin enzyme immunoassay (EIA) for toxins A/B (high specificity, lower sensitivity). Many laboratories use multistep algorithms (GDH screening followed by toxin EIA or NAAT) to improve diagnostic accuracy while avoiding overdiagnosis of colonisation.

Testing should be performed only on unformed stools, not formed stools or rectal swabs. Repeat testing within 7 days of a negative result is not recommended as it yields low positive predictive value and does not improve clinical outcomes. For patients with ileus, polymerase chain reaction (PCR) testing of stool or rectal swab may be appropriate.

Risk Factors

Risk factors for CDI include antibiotic exposure (especially broad-spectrum agents, fluoroquinolones, clindamycin, cephalosporins), advanced age greater than 65 years, hospitalisation, underlying comorbidities (inflammatory bowel disease, chronic kidney disease, immunosuppression), proton pump inhibitor use, and prior CDI. Antibiotic exposure is the most important modifiable risk factor, with risk persisting for up to 3 months after cessation.

Prevention: Contact Precautions

Contact precautions are essential for preventing C. difficile transmission. Patients with suspected or confirmed CDI should be placed in a private room with dedicated equipment (stethoscope, blood pressure cuff, thermometer). If private rooms are unavailable, cohort CDI patients together. Healthcare workers should wear gloves and gowns when entering patient rooms and perform hand hygiene with soap and water after removing gloves—alcohol-based hand rubs are ineffective against C. difficile spores.

Environmental cleaning is critical due to environmental persistence of C. difficile spores. Sporicidal agents including bleach (1000-5000 ppm chlorine) or EPA-registered sporicidal disinfectants should be used for daily and terminal cleaning. Particular attention should be paid to high-touch surfaces (bed rails, bedside tables, call buttons, bathroom facilities). Environmental monitoring with fluorescent markers or ATP testing can evaluate cleaning effectiveness.

Patients should remain on contact precautions for the duration of diarrhoea, though practice patterns vary regarding discontinuation after resolution. CDC recommends continuing precautions for at least 48 hours after diarrhoea resolution, while some facilities continue until discharge. Hand hygiene with soap and water remains essential throughout the hospitalisation.

Prevention: Antibiotic Stewardship

Antibiotic stewardship is the cornerstone of CDI prevention. Key strategies include:

• Avoid unnecessary antibiotics: Prescribe antibiotics only when clearly indicated. Up to 50% of antibiotic prescriptions in hospitals are inappropriate or unnecessary.
• Narrow spectrum when possible: Use the narrowest spectrum agent effective for the presumed infection. For example, amoxicillin rather than amoxicillin-clavulanate for uncomplicated cellulitis, or first-generation cephalosporins rather than third-generation for many surgical prophylaxis indications.
• Avoid high-risk agents: Avoid clindamycin, fluoroquinolones, and broad-spectrum cephalosporins when alternative agents exist. These antibiotics have the strongest association with CDI.
• Limit duration: Prescribe the shortest effective duration of antibiotics. Many infections can be treated effectively with 5-7 days rather than 10-14 days, particularly for uncomplicated infections.
• De-escalate based on cultures: Review culture results promptly and de-escalate from empiric broad-spectrum therapy to targeted therapy when appropriate.

Healthcare facility-wide antibiotic stewardship programs reduce CDI rates by 30-50%. Multidisciplinary stewardship teams including infectious diseases physicians, pharmacists, microbiologists, and infection control practitioners implement guidelines, provide audit and feedback, and educate prescribers.

Management

CDI management depends on disease severity. For non-severe infection (white blood cell count below 15,000/µL, creatinine below 1.5 times baseline), oral vancomycin 125 mg four times daily for 10 days or oral fidaxomicin 200 mg twice daily for 10 days is recommended. Fidaxomicin is superior to vancomycin for sustained clinical response (lower recurrence rates), though more expensive.

For severe infection (WBC ≥15,000/µL or creatinine ≥1.5 times baseline), oral vancomycin 125 mg four times daily for 10 days is preferred. For severe complicated infection (hypotension, shock, ileus, toxic megacolon), combined therapy with oral vancomycin plus intravenous metronidazole 500 mg three times daily is recommended, though evidence for metronidazole efficacy is limited and vancomycin alone may be sufficient. Oral vancomycin can be administered via nasogastric tube for patients with ileus or when oral administration is not possible.

For recurrent CDI (≥3 episodes), strategies include pulsed vancomycin regimen, fidaxomicin, or fecal microbiota transplantation (FMT). FMT demonstrates cure rates greater than 85% for multiply recurrent CDI and is recommended for patients with ≥3 recurrences despite appropriate antibiotic therapy. Antibodies against C. difficile toxins (bezlotoxumab) can be used as adjunctive therapy for patients at high risk of recurrence.

Supportive care includes fluid resuscitation, electrolyte replacement (particularly magnesium and potassium which may be depleted due to diarrhoea), and avoidance of antimotility agents which may precipitate toxic megacolon. Surgical consultation should be obtained early for patients with signs of toxic megacolon (colonic distension, systemic toxicity) as subtotal colectomy may be life-saving.

---

Surveillance and Quality Improvement

Surveillance Programs

Active surveillance for HAIs is essential for identifying baseline rates, detecting outbreaks, and measuring the impact of prevention interventions. Surveillance should focus on device-associated infections (CLABSI, CAUTI, VAP) using standardised definitions from the CDC or equivalent national programs. Data should be reported as infection rates per device-days to allow comparison over time and between units.

Process measures (bundle compliance) should be tracked alongside outcome measures (infection rates). Bundle compliance greater than 90% is associated with maximal reduction in HAIs. Examples of process measures include: percentage of central line insertions with maximal barrier precautions, percentage of central lines with appropriate indication, percentage of ventilated patients with head-of-bed elevation greater than 30 degrees, and percentage of urinary catheters with appropriate indication.

Multidisciplinary Teams

Effective HAI prevention requires multidisciplinary collaboration. Infection control practitioners collect and analyse surveillance data, identify clusters requiring investigation, and implement control measures. ICU physicians and nurses are responsible for implementing prevention bundles at the bedside. Pharmacists participate in antimicrobial stewardship programs. Environmental services ensure appropriate cleaning and disinfection. Hospital administrators provide resources and support for prevention programs.

Outbreak Investigation

When increased HAI rates or clustering are detected, outbreak investigation should be initiated promptly. Steps include confirming the outbreak (comparing rates to baseline), defining cases, generating hypotheses about sources, implementing control measures, and evaluating effectiveness. Typing of organisms (pulsed-field gel electrophoresis, whole genome sequencing) can identify related strains and point to common sources. Outbreak control may involve cohorting patients, reinforcing contact precautions, environmental decontamination, and auditing compliance with prevention bundles.

Benchmarking

HAI rates should be benchmarked against national or international databases to allow meaningful comparison. In Australia, the National Hand Hygiene Initiative and Victorian Healthcare Associated Infection Surveillance System (VICNISS) provide benchmarking data. The CDC NHSN (National Healthcare Safety Network) provides extensive US data. Benchmarking should account for patient case-mix, as ICUs caring for higher-acuity patients have higher baseline infection rates even with optimal prevention practices.

---

Antimicrobial Stewardship

Principles

Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials to improve patient outcomes, minimise antimicrobial resistance, and reduce healthcare costs without compromising patient care. Core principles include prescribing antibiotics only when clearly indicated, selecting the most appropriate agent based on likely pathogens and local resistance patterns, using the narrowest spectrum effective, de-escalating based on culture results, and limiting duration to the shortest effective course.

Stewardship Interventions

Effective stewardship interventions include:

• Prospective audit and feedback: Review of antibiotic prescriptions with feedback to prescribers. This intervention reduces inappropriate use by 20-30% and is one of the most effective stewardship strategies.
• Formulary restriction: Requiring pre-approval for selected antibiotics (carbapenems, linezolid, daptomycin). Restriction reduces use of targeted agents and may improve prescribing patterns.
• Clinical pathways: Standardised approaches for common infections (community-acquired pneumonia, intra-abdominal infections) with specified agent selection and duration.
• De-escalation protocols: Systematic review of culture results at 48-72 hours with prompt de-escalation from empiric broad-spectrum therapy to targeted agents.
• Duration guidelines: Recommended treatment durations for specific infections, with automatic stop orders or pharmacist-initiated dose adjustments.
• Education: Regular education for prescribers on antimicrobial prescribing, resistance patterns, and stewardship principles.

Impact on HAIs

Antimicrobial stewardship programs reduce HAI rates by 15-30% and reduce antimicrobial resistance by 20-40%. Programs demonstrating impact include reduced C. difficile infection rates (due to reduced broad-spectrum antibiotic exposure), reduced VAP rates (through appropriate selection and duration of empiric therapy), and reduced MDRO infections. Stewardship is complementary to infection control practices—the most effective programs integrate both approaches.

---

Australian and New Zealand Context

National Standards

The Australian National Safety and Quality Health Service (NSQHS) Standards include Standard 3: Preventing and Controlling Healthcare-Associated Infection, which outlines requirements for healthcare organisations. Requirements include implementing infection prevention and control systems, using standard and transmission-based precautions, managing clinical waste, reprocessing reusable medical equipment, and reporting HAI data. Organisations must have nominated infection control professionals and committees responsible for HAI prevention.

Indigenous Health Considerations

Indigenous Australians experience higher rates of HAIs compared with non-Indigenous Australians, reflecting underlying health disparities, higher comorbidity burden, and barriers to accessing preventative healthcare. Factors contributing to higher HAI rates include higher rates of diabetes and chronic kidney disease (impairing immune function), delayed presentation with advanced disease, higher rates of chronic bacterial colonisation, and challenges with post-discharge follow-up in remote communities.

Culturally appropriate care is essential for effective HAI prevention in Aboriginal and Torres Strait Islander patients. This includes involvement of Aboriginal Health Workers and Aboriginal Liaison Officers, culturally sensitive communication acknowledging family decision-making structures, respect for traditional healing practices where they complement conventional care, and awareness of specific cultural considerations around touch, gender, and body privacy. For patients being transferred to remote communities, coordination with local Aboriginal Medical Services and provision of clear follow-up instructions are essential.

Māori Health Considerations

In New Zealand, Māori patients experience similar disparities in HAI rates and outcomes. Whānau (family) involvement in care decisions is important, with kaumātua (elders) often playing central roles. Understanding tikanga Māori (Māori protocols) regarding tapu (sacredness) of the body, particularly around bodily fluids and medical waste disposal, is essential. Spiritual considerations including karakia (prayer) and involvement of hospital chaplains or Māori spiritual providers should be respected.

Remote and Rural Considerations

Remote and rural ICUs face unique challenges for HAI prevention. Limited resources may constrain availability of dedicated infection control staff, single rooms for isolation, or specialised equipment such as antimicrobial-impregnated catheters. Transfer of patients to tertiary centres introduces risks of cross-infection during transport and between facilities. Workforce limitations and less frequent medical cover may delay removal of unnecessary devices.

Strategies for remote and rural ICUs include strong partnerships with larger tertiary centres for telehealth infection control support, simplified bundle protocols that are easy to implement with limited resources, reliance on standard bundles (which are effective regardless of facility size), and robust communication during patient transfers. The Royal Flying Doctor Service (RFDS) plays a critical role in transferring critically ill patients from remote areas to tertiary ICUs, with infection prevention measures essential during retrieval.

Australian Guidelines

Australian guidelines for HAI prevention include:

• Australian Commission on Safety and Quality in Health Care (ACSQHC): NSQHS Standards, National Infection Prevention Guidelines
• Australian Guidelines for the Prevention and Control of Infection in Healthcare (2019): Comprehensive guidance covering all aspects of HAI prevention
• Australian and New Zealand Intensive Care Society (ANZICS): Guidelines for various aspects of ICU care including infection prevention
• Therapeutic Guidelines: Antibiotic prescribing guidelines supporting antimicrobial stewardship

---

Evidence Summary

CLABSI

• Pronovost et al., NEJM 2006 (PMID 16844567): Michigan Keystone ICU study demonstrating 66% reduction in CLABSI (2.7 to 0.9/1000 line-days) with implementation of central line bundle.
• O'Grady et al., CID 2011 (PMID 21653587): IDSA guidelines for intravascular catheter-related infection, providing evidence-based recommendations for prevention, diagnosis, and management.
• Lederer et al., Ann Intern Med 2015 (PMID 26054379): Systematic review showing chlorhexidine skin antisepsis superior to povidone-iodine (RR 0.49).
• Maki et al., Lancet Infect Dis 2006 (PMID 16890891): Demonstrated benefit of antimicrobial-impregnated catheters (minocycline-rifampin) for CLABSI reduction.

CAUTI

• Gould et al., Infect Control Hosp Epidemiol 2010 (PMID 20487586): SHEA/IDSA compendium of strategies to prevent catheter-associated urinary tract infection.
• Lo et al., Clin Infect Dis 2014 (PMID 24842262): Demonstrated success of CAUTI prevention program in 603 hospitals (32% reduction in CAUTI rates).
• Saint et al., BMJ 2013 (PMID 23558152): Systematic review of interventions to prevent CAUTI, highlighting importance of avoiding unnecessary catheterisation.

VAP

• Drakulovic et al., Lancet 1999 (PMID 10408339): Randomised trial showing 34% reduction in VAP with semi-recumbent positioning (45° head-of-bed elevation).
• Kress et al., NEJM 2000 (PMID 10688602): Randomised trial demonstrating benefit of daily sedation interruption (median ventilation 4.9 vs 7.9 days).
• Schweickert et al., JAMA 2009 (PMID 19162696): Early physical and occupational therapy in mechanically ventilated patients reduced delirium and improved outcomes.
• Safdar et al., JAMA 2005 (PMID 15956631): Meta-analysis of VAP prevention strategies, confirming effectiveness of subglottic secretion drainage and semi-recumbent positioning.

SSI

• Berrios-Torres et al., JAMA Surg 2017 (PMID 28464141): CDC guideline for surgical site infection prevention, 2017 update.
• Allegranzi et al., Lancet 2016 (PMID 27814983): WHO guidelines for prevention of surgical site infection.
• de Lissovoy et al., JAMA Surg 2009 (PMID 19372556): Surgical site infection: incidence and impact on healthcare resource use.
• Classen et al., NEJM 1992 (PMID 1346135): Demonstrated optimal timing of antibiotic prophylaxis (within 2 hours before incision).
• Kurz et al., Lancet 1996 (PMID 8972426): Perioperative normothermia reduced SSI rate from 19% to 6% in colorectal surgery.
• Belda et al., JAMA 2005 (PMID 15968009): Randomised trial showing 50% reduction in SSI with 80% perioperative FiO2.

C. difficile

• McDonald et al., MMWR 2007 (PMID 17680378): SHEA/IDSA guideline for C. difficile infection in adults.
• Leffler and Lamont, NEJM 2015 (PMID 26225061): Comprehensive review of C. difficile epidemiology, pathogenesis, and management.
• van Nood et al., NEJM 2013 (PMID 23324495): Randomised trial of fecal microbiota transplantation for recurrent C. difficile (81% cure vs 31% with vancomycin).
• Zar et al., Clin Infect Dis 2007 (PMID 17475335): Demonstrated superior efficacy of vancomycin vs metronidazole for severe C. difficile infection.

Antimicrobial Stewardship

• Barlam et al., CID 2016 (PMID 27077694): SHEA/IDSA guideline for implementing antimicrobial stewardship programs.
• Burgess and Mabasa, J Infect Dis 2014 (PMID 24212573): Demonstrated that antimicrobial stewardship programs reduce antimicrobial use and C. difficile infection.
• Karababa et al., Infect Control Hosp Epidemiol 2020 (PMID 32576782): Systematic review of antimicrobial stewardship interventions in ICUs.

---

Clinical Decision-Making Scenarios

Scenario: Device Removal Decisions

A 65-year-old man with end-stage liver failure has had a central venous catheter for 14 days for total parenteral nutrition. Blood cultures are growing coagulase-negative staphylococci. The patient is clinically stable, afebrile, with no evidence of sepsis.

The decision to remove or retain the catheter requires balancing several factors. For this patient with coagulase-negative staphylococci, which are common skin contaminants, I would first assess whether multiple culture sets are positive with the same organism, which supports true infection rather than contamination. A differential time to positivity (greater than 2 hours earlier from central line vs peripheral blood cultures) would support the catheter as the source. Catheter tip culture would provide additional confirmation.

Given the patient's stability and limited vascular access options (liver failure predisposes to coagulopathy making line insertion difficult), I might retain the catheter with antibiotic lock therapy in conjunction with systemic antibiotics. However, I would monitor closely for clinical deterioration and prepare for line removal if infection worsens or fails to respond to therapy. If the patient were unstable, had tunnel or pocket infection, or the organism was S. aureus or Pseudomonas, I would remove the catheter immediately.

Scenario: VAP Diagnostic Uncertainty

A 55-year-old woman with severe ARDS has been ventilated for 12 days. She develops new fever (38.2°C) and new infiltrates on chest X-ray. Sputum cultures are growing Candida albicans, and the patient has received broad-spectrum antibiotics for 10 days.

This scenario highlights the diagnostic challenges of VAP. Candida in respiratory specimens usually represents colonisation rather than true infection, particularly in patients receiving broad-spectrum antibiotics. True Candida pneumonia is rare and usually occurs in neutropenic patients or those with severe immunosuppression.

For this patient, I would consider alternative diagnoses: pulmonary oedema (volume overload in ARDS), atelectasis, thromboembolic disease, and transfusion-related lung injury. Biomarkers such as procalcitonin may help distinguish bacterial infection from inflammation (procalcitonin typically elevated in bacterial infection but not in non-infectious inflammation).

If clinical concern for bacterial VAP persists, I would obtain bronchoalveolar lavage with quantitative cultures to improve diagnostic specificity. BAL with quantitative threshold greater than 10^4 CFU/mL is more specific than tracheal aspiration, which can sample colonised upper airway. Empiric antibiotics should be withheld or discontinued if there's low clinical suspicion, to avoid further antimicrobial pressure and resistance development.

Scenario: Recurrent C. difficile

A 70-year-old man with stage IV colon cancer has experienced three episodes of C. difficile infection in the past 6 months, each treated with vancomycin. He develops recurrent diarrhoea with positive stool PCR for C. difficile.

For multiply recurrent C. difficile (≥3 recurrences), standard vancomycin therapy is insufficient. Options include pulsed vancomycin regimens (e.g., 125 mg four times daily for 14 days, then every other day for 7 days, then every third day for 7 days), fidaxomicin 200 mg twice daily for 10 days (higher cure rate and lower recurrence than vancomycin), or fecal microbiota transplantation (FMT).

FMT is the most effective option for multiply recurrent CDI, with cure rates greater than 85% in randomised trials. FMT works by restoring normal gut microbiome disrupted by antibiotics. For this patient with limited life expectancy, FMT may be particularly valuable to prevent recurrent infections that significantly impact quality of life. Discussion with infectious diseases and gastroenterology specialists is essential, and appropriate donor screening for transmissible pathogens is mandatory.

Infection control remains critical with recurrent CDI. The patient should remain on contact precautions during symptomatic periods, and household members should be educated about hand hygiene and environmental cleaning. Some guidelines recommend continuing precautions for the duration of hospitalisation in patients with recurrent CDI.

---

Assessment Content

SAQ Practice Question 1

SAQ Practice Question 3

Viva Scenario 3

Viva Scenario 4

---

Clinical Algorithms

CLABSI Evaluation Algorithm

1. Recognise signs: Fever (greater than 38°C), hypothermia (below 36°C), hypotension, leukocytosis or leukopenia, altered mental status, or unexplained metabolic acidosis in patient with central line.

2. Obtain cultures:

   • At least two sets of blood cultures (preferably one percutaneous, one through each line lumen)
   • Consider catheter tip culture if line is removed
   • Additional cultures as clinically indicated (urine, sputum, wound)

3. Initiate empiric antibiotics:

   • Cover MRSA (vancomycin or linezolid)
   • Cover gram-negatives including Pseudomonas (piperacillin-tazobactam, cefepime, meropenem)
   • Adjust based on patient risk factors (allergies, recent antibiotics, prior colonisation)

4. Source control decisions:

   • Remove line if: Unstable, tunnel or pocket infection, S. aureus or Pseudomonas, persistent infection (greater than 72 hours of appropriate antibiotics), catheter-related thrombophlebitis
   • Consider retention if: Limited access, low-virulence organism (skin commensals), clinical improvement

5. Duration of therapy:

   • Uncomplicated: 7-14 days
   • Complicated (endocarditis, septic thrombophlebitis): 4-6 weeks
   • Obtain echocardiography for S. aureus bacteraemia if risk factors or persistent infection

VAP Evaluation Algorithm

1. Recognise signs: New infiltrate on CXR plus two of: fever, leukocytosis/leukopenia, purulent secretions. Occurs greater than 48 hours after intubation.

2. Obtain diagnostic specimens:

   • Sputum via tracheal aspiration
   • BAL with quantitative cultures if available (greater than 10^4 CFU/mL threshold)
   • Blood cultures (at least 2 sets)
   • Consider biomarkers (procalcitonin) to distinguish infection from inflammation

3. Assess differential diagnoses:

   • Pulmonary oedema (volume overload, cardiogenic)
   • Atelectasis
   • Pulmonary embolism
   • ARDS progression
   • Drug reaction or transfusion-related lung injury

4. Initiate empiric antibiotics:

   • Cover MRSA (vancomycin or linezolid)
   • Cover Pseudomonas and resistant gram-negatives (piperacillin-tazobactam, cefepime, meropenem)
   • Consider double antipseudomonal coverage if high MDRO risk
   • Adjust for renal/hepatic function, allergies

5. De-escalate:

   • Review cultures at 48-72 hours
   • Stop unnecessary agents (e.g., vancomycin if no MRSA)
   • Narrow spectrum based on susceptibility

6. Duration:

   • Uncomplicated VAP: 7-8 days
   • May consider shorter courses (5-7 days) if rapid response
   • Longer courses (14-21 days) only for complicated infections (lung abscess, empyema, bacteremia)

C. difficile Evaluation Algorithm

1. Recognise signs: ≥3 unformed stools in 24 hours, plus: fever, leukocytosis, abdominal pain, or ileus.

2. Obtain stool specimen:

   • Test only unformed stool (no formed stool or rectal swab)
   • NAAT for toxin genes or GDH plus toxin EIA algorithm
   • One test is sufficient; repeat testing within 7 days not recommended

3. Assess severity:

   • Mild: WBC below 15,000, creatinine below 1.5× baseline, no ileus
   • Severe: WBC ≥15,000 or creatinine ≥1.5× baseline
   • Severe-complicated: Hypotension, shock, ileus, toxic megacolon

4. Management based on severity:

   • Mild: Vancomycin 125 mg QID ×10 days OR fidaxomicin 200 mg BID ×10 days
   • Severe: Vancomycin 125 mg QID ×10 days (preferred)
   • Severe-complicated: Vancomycin 125 mg QID + metronidazole 500 mg IV TID

5. Recurrent infection (≥3 recurrences):

   • Consider pulsed vancomycin regimen
   • Consider fidaxomicin (lower recurrence than vancomycin)
   • Consider fecal microbiota transplantation (greater than 85% cure rate)

6. Infection control:

   • Contact precautions (gown, gloves)
   • Private room or cohort with CDI patients
   • Hand hygiene with soap and water (alcohol ineffective against spores)
   • Environmental cleaning with sporicidal agents (bleach)

---

SAQ Practice Question 2

Viva Scenario 1

Viva Scenario 2

---

Multidrug-Resistant Organisms

Overview

Multidrug-resistant organisms (MDROs) represent one of the most pressing challenges in modern intensive care medicine. These organisms have developed resistance to multiple antimicrobial agents, often including first-line empiric therapy choices. MDROs are associated with higher mortality, longer hospital stays, increased costs, and limited treatment options. The most clinically important MDROs in ICUs include methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), carbapenem-resistant Enterobacterales (CRE), extended-spectrum beta-lactamase (ESBL)-producing Enterobacterales, and extensively drug-resistant (XDR) or pan-drug-resistant (PDR) Pseudomonas aeruginosa and Acinetobacter baumannii.

MRSA

Methicillin-resistant Staphylococcus aureus emerged in the 1960s shortly after methicillin introduction and has since become endemic in hospitals worldwide. MRSA carries the mecA gene encoding an altered penicillin-binding protein (PBP2a) with low affinity for beta-lactam antibiotics. In addition to methicillin and all beta-lactams, MRSA is often resistant to macrolides, fluoroquinolones, and clindamycin. Vancomycin, teicoplanin, linezolid, daptomycin, and ceftaroline are primary treatment options.

ICU patients are at particularly high risk for MRSA acquisition due to invasive devices, antimicrobial exposure, and close contact with healthcare workers. Risk factors for MRSA infection include prior MRSA colonisation, recent hospitalisation, prior antibiotic use (particularly fluoroquinolones), chronic wounds, dialysis, and prolonged ICU stay. MRSA bacteraemia carries mortality rates of 20-40%, approximately twice that of MSSA bacteraemia.

Prevention of MRSA transmission requires comprehensive infection control measures. Active surveillance cultures (nasal swabs) to identify colonised patients allow for implementation of targeted contact precautions and decolonisation protocols. Decolonisation regimens typically include mupirocin nasal ointment twice daily for 5-10 days plus chlorhexidine gluconate washes daily. Universal decolonisation without prior screening has also demonstrated effectiveness in reducing MRSA infections in some studies, though concerns about resistance development limit widespread adoption.

Contact precautions (gown and gloves) for MRSA-colonised or infected patients are standard. Environmental cleaning with sporicidal agents is important, as MRSA can survive for months on dry surfaces. Hand hygiene remains the most important measure for preventing transmission.

VRE

Vancomycin-resistant enterococci, particularly Enterococcus faecium and E. faecalis, emerged in the late 1980s and have since spread globally. Resistance develops through acquisition of vanA or vanB genes which alter the peptidoglycan binding site targeted by vancomycin. VRE typically also demonstrate resistance to ampicillin and high-level aminoglycoside resistance, severely limiting treatment options. Linezolid, daptomycin, tigecycline, and newer agents such as oritavancin are primary therapeutic options.

Risk factors for VRE acquisition include prolonged hospitalisation, exposure to vancomycin or broad-spectrum antibiotics (particularly cephalosporins), immunosuppression, severe underlying illness, and prior VRE colonisation. VRE can survive for months on environmental surfaces, requiring thorough terminal cleaning with sporicidal disinfectants. Contact precautions for colonised or infected patients are essential, though the optimal duration of precautions remains debated. Some institutions maintain precautions for the duration of hospitalisation, while others discontinue after documented clearance (three consecutive negative cultures collected at least one week apart).

CRE

Carbapenem-resistant Enterobacterales represent a critical threat to patient safety. Carbapenem resistance develops through two primary mechanisms: production of carbapenemase enzymes (KPC, NDM, OXA-48, VIM, IMP) that hydrolyse carbapenems, and combinations of extended-spectrum beta-lactamase (ESBL) plus porin loss that reduces carbapenem entry. CRE infections carry mortality rates of 30-50% for invasive infections, with treatment options often limited to polymyxins (colistin), tigecycline, fosfomycin, and aminoglycosides, all of which have significant toxicity or limited tissue penetration.

Risk factors for CRE colonisation and infection include recent international healthcare exposure (particularly to countries with high CRE prevalence), prolonged hospitalisation, exposure to carbapenems or fluoroquinolones, indwelling devices, and prior colonisation with resistant organisms. CRE spreads through patient-to-patient transmission (contaminated equipment, healthcare worker hands) and can persist on environmental surfaces for weeks. Prevention relies on aggressive contact precautions, environmental cleaning with chlorine-based disinfectants, antimicrobial stewardship (limiting carbapenem use), and active surveillance with rectal screening cultures, particularly for patients with recent international healthcare exposure.

ESBL-Producing Enterobacterales

Extended-spectrum beta-lactamase-producing organisms (most commonly E. coli and Klebsiella pneumoniae) hydrolyse third-generation cephalosporins and aztreonam, leaving carbapenems, fosfomycin, nitrofurantoin (for urinary infections), and piperacillin-tazobactam (some strains) as primary treatment options. ESBL producers remain susceptible to carbapenems, though excessive carbapenem use drives CRE emergence.

ESBL prevalence has increased dramatically worldwide, with community-acquired ESBL urinary tract infections becoming increasingly common. Risk factors include recent antibiotic use (particularly fluoroquinolones and cephalosporins), recent hospitalisation, travel to high-prevalence regions, and residence in long-term care facilities. Prevention strategies focus on antimicrobial stewardship to limit unnecessary cephalosporin use and environmental cleaning to prevent nosocomial spread.

XDR Pseudomonas and Acinetobacter

Extensively drug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii are particularly problematic in ICU patients with prolonged ventilation. These organisms acquire resistance through multiple mechanisms: beta-lactamase production (ESBL, carbapenemases), efflux pumps, porin loss, and target site mutations. Treatment often requires combination therapy (colistin plus another agent such as beta-lactam, tigecycline, or rifampin) despite limited evidence for combination benefit and high toxicity risk.

Acinetobacter baumannii has remarkable environmental persistence, surviving for months on dry surfaces and demonstrating resistance to routine disinfectants. This environmental resilience contributes to prolonged outbreaks in ICUs, requiring aggressive environmental decontamination, dedicated equipment, and often cohorting of affected patients. Pseudomonas aeruginosa also survives well in moist environments including sinks, shower drains, and respiratory equipment, requiring routine environmental disinfection protocols.

Antimicrobial Resistance Mechanisms

Understanding resistance mechanisms informs both prevention strategies and antibiotic selection. Beta-lactamase enzymes hydrolyse beta-lactam antibiotics, with ESBLs and carbapenemases representing the most clinically important. Altered target site resistance includes MRSA (PBP2a), VRE (altered peptidoglycan terminus), and fluoroquinolone resistance (DNA gyrase/topoisomerase mutations). Efflux pumps actively export antibiotics from bacterial cells, conferring multi-class resistance (particularly in Pseudomonas). Porin loss reduces antibiotic entry into gram-negative bacteria, particularly contributing to carbapenem resistance in combination with ESBL. Biofilm formation creates a physical barrier to antibiotic penetration and supports bacterial persistence despite antimicrobial exposure.

---

Hand Hygiene and Standard Precautions

Hand Hygiene

Hand hygiene is the single most effective measure for preventing HAIs. Proper hand hygiene reduces transmission of pathogens from colonised or infected patients to other patients, between patients, and between contaminated environments and patients. The WHO "Five Moments for Hand Hygiene" provide a framework for appropriate handwashing: before touching a patient, before clean/aseptic procedures, after body fluid exposure risk, after touching a patient, and after touching patient surroundings.

Alcohol-based hand rubs are preferred for routine hand hygiene due to rapid action (15-30 seconds), availability, and skin tolerance compared with soap and water. However, soap and water are required when hands are visibly soiled, after caring for patients with Clostridioides difficile or norovirus (alcohol ineffective against spores), and after exposure to certain chemicals (e.g., chlorine-based disinfectants).

Hand hygiene compliance in ICUs typically ranges from 40-60%, with significant room for improvement. Multimodal improvement strategies including education, visual reminders, access to alcohol rubs, performance feedback, and institutional safety climate can improve compliance to greater than 80%. High compliance (greater than 90%) is associated with maximal HAI reduction. Observational studies demonstrate that healthcare workers most frequently perform hand hygiene after patient contact and before patient contact, but compliance is lower before clean procedures and after body fluid exposure.

Standard Precautions

Standard precautions apply to all patients regardless of presumed infection status and are the foundation of infection prevention. Components include hand hygiene, use of personal protective equipment (gloves, gowns, masks, eye protection) based on anticipated exposure, safe injection practices, respiratory hygiene/cough etiquette, appropriate handling of potentially contaminated equipment or linen in the environment, and environmental controls.

Gloves should be worn when anticipating contact with blood, body fluids, secretions, excretions, non-intact skin, or mucous membranes. However, gloves do not replace hand hygiene—hands must be cleaned before donning and after removing gloves. Gowns are indicated when anticipating clothing or skin contamination. Masks and eye protection are required when anticipating splashes or sprays of blood or body fluids (e.g., intubation, suctioning).

Safe injection practices include using aseptic technique, using single-use vials for single patients, avoiding contamination of multi-dose vials, and never administering medications from the same syringe to multiple patients. Outbreaks of bloodborne viruses (HBV, HCV) and bacterial infections have resulted from unsafe injection practices.

Transmission-Based Precautions

Transmission-based precautions (contact, droplet, airborne) are implemented in addition to standard precautions based on the suspected or confirmed mode of transmission for specific pathogens. Contact precautions (gown and gloves) are used for organisms transmitted by direct or indirect contact (MRSA, VRE, CRE, C. difficile, RSV). Droplet precautions (surgical mask within 1 metre) are used for organisms transmitted via large respiratory droplets (influenza, COVID-19, pertussis). Airborne precautions (negative pressure room, N95 respirator) are used for organisms transmitted via small particle aerosols (tuberculosis, measles, varicella).

ICU patients often require multiple concurrent precautions (e.g., contact plus droplet). This increases complexity of care and may delay interventions while donning PPE. Education and PPE accessibility are essential to ensure appropriate compliance. Some evidence suggests that single rooms for all patients may be as effective as contact precautions for preventing organism transmission, though this approach requires significant infrastructure investment.

Environmental Cleaning

Environmental surfaces serve as reservoirs for MDROs and can contribute to cross-transmission between patients. High-touch surfaces (bed rails, bedside tables, call buttons, intravenous pumps, ventilator surfaces) are most frequently contaminated and require regular cleaning. Disinfectant choice depends on target organisms—bleach or chlorine-based agents are required for C. difficile spores, while alcohol-based agents are effective for vegetative bacteria and viruses.

Environmental monitoring using fluorescent markers, ATP testing, or microbiological cultures provides feedback on cleaning effectiveness. Terminal cleaning (thorough cleaning after patient discharge) is particularly important after caring for patients with MDROs, with verification of cleaning using objective monitoring tools. UV-C disinfection or hydrogen peroxide vapour can supplement manual cleaning, particularly during outbreak investigations, though these modalities add cost and are not substitutes for thorough manual cleaning.

Water sources in ICUs (sinks, showers, faucets) can harbour gram-negative organisms, particularly Pseudomonas and Acinetobacter. Water system maintenance, routine disinfection, and design modifications (gooseneck faucets, sink location away from patient care areas) reduce water-associated infection risk.

---

Surveillance and Quality Improvement

Surveillance Programs

Active surveillance for HAIs is essential for identifying baseline rates, detecting outbreaks, and measuring impact of prevention interventions. Surveillance should focus on device-associated infections (CLABSI, CAUTI, VAP) using standardised definitions from CDC or equivalent national programs. Data should be reported as infection rates per device-days to allow comparison over time and between units.

Process measures (bundle compliance) should be tracked alongside outcome measures (infection rates). Bundle compliance greater than 90% is associated with maximal reduction in HAIs. Examples of process measures include: percentage of central line insertions with maximal barrier precautions, percentage of central lines with appropriate indication, percentage of ventilated patients with head-of-bed elevation greater than 30 degrees, and percentage of urinary catheters with appropriate indication.

Surveillance data should be analysed for trends over time, comparisons between units or hospitals, and identification of high-risk patient populations or practices. Statistical process control charts (p-charts, u-charts) can help distinguish expected variation from true increases requiring intervention. Regular reporting to clinical staff, hospital leadership, and infection control committees ensures that data inform quality improvement efforts.

Multidisciplinary Teams

Effective HAI prevention requires multidisciplinary collaboration. Infection control practitioners collect and analyse surveillance data, identify clusters requiring investigation, and implement control measures. ICU physicians and nurses are responsible for implementing prevention bundles at the bedside. Pharmacists participate in antimicrobial stewardship programs. Environmental services ensure appropriate cleaning and disinfection. Hospital administrators provide resources and support for prevention programs.

Regular multidisciplinary rounds focusing on infection prevention can identify gaps in implementation, promote shared understanding, and ensure accountability. Including bedside nurses who deliver the majority of care in decision-making improves engagement and practical implementation of prevention strategies. Quality improvement teams using Plan-Do-Study-Act (PDSA) cycles can systematically test and implement changes to improve bundle compliance and reduce infection rates.

Outbreak Investigation

When increased HAI rates or clustering are detected, outbreak investigation should be initiated promptly. Steps include confirming the outbreak (comparing rates to baseline), defining cases, generating hypotheses about sources, implementing control measures, and evaluating effectiveness. Typing of organisms (pulsed-field gel electrophoresis, whole genome sequencing) can identify related strains and point to common sources.

Outbreak control may involve cohorting patients (grouping affected patients together with dedicated staff), reinforcing contact precautions, environmental decontamination, and auditing compliance with prevention bundles. Healthcare worker screening (including asymptomatic carriers) may be indicated during sustained outbreaks with certain organisms (MRSA, Group A Streptococcus). Communication with public health authorities is required for notifiable conditions.

After outbreak resolution, a formal outbreak report should document the timeline, investigation findings, interventions implemented, and lessons learned. This documentation improves preparedness for future outbreaks and provides evidence for resource allocation to prevention programs.

Benchmarking

HAI rates should be benchmarked against national or international databases to allow meaningful comparison. In Australia, National Hand Hygiene Initiative and Victorian Healthcare Associated Infection Surveillance System (VICNISS) provide benchmarking data. The CDC NHSN (National Healthcare Safety Network) provides extensive US data. Benchmarking should account for patient case-mix, as ICUs caring for higher-acuity patients have higher baseline infection rates even with optimal prevention practices.

Risk adjustment using standardised infection ratios (SIRs) allows comparison between institutions with different patient populations. SIR is calculated as observed infections divided by expected infections based on patient risk factors (device utilisation, patient comorbidities). SIR greater than 1 indicates higher-than-expected infection rates, requiring investigation and quality improvement.

---

Antimicrobial Stewardship

Principles

Antimicrobial stewardship is a coordinated program that promotes appropriate use of antimicrobials to improve patient outcomes, minimise antimicrobial resistance, and reduce healthcare costs without compromising patient care. Core principles include prescribing antibiotics only when clearly indicated, selecting the most appropriate agent based on likely pathogens and local resistance patterns, using the narrowest spectrum effective, de-escalating based on culture results, and limiting duration to the shortest effective course.

Stewardship Interventions

Effective stewardship interventions include:

• Prospective audit and feedback: Review of antibiotic prescriptions with feedback to prescribers. This intervention reduces inappropriate use by 20-30% and is one of the most effective stewardship strategies.
• Formulary restriction: Requiring pre-approval for selected antibiotics (carbapenems, linezolid, daptomycin). Restriction reduces use of targeted agents and may improve prescribing patterns.
• Clinical pathways: Standardised approaches for common infections (community-acquired pneumonia, intra-abdominal infections) with specified agent selection and duration.
• De-escalation protocols: Systematic review of culture results at 48-72 hours with prompt de-escalation from empiric broad-spectrum therapy to targeted agents.
• Duration guidelines: Recommended treatment durations for specific infections, with automatic stop orders or pharmacist-initiated dose adjustments.
• Education: Regular education for prescribers on antimicrobial prescribing, resistance patterns, and stewardship principles.

ICU-specific stewardship challenges include high prevalence of broad-spectrum use, limited diagnostic certainty (distinguishing infection from inflammation), and therapeutic drug monitoring considerations (e.g., vancomycin, aminoglycosides). ICU stewardship programs should include intensivist leadership, dedicated infectious diseases pharmacist involvement, integration with antimicrobial resistance surveillance data, and focus on high-impact interventions such as de-escalation prompts and duration limits.

Impact on HAIs

Antimicrobial stewardship programs reduce HAI rates by 15-30% and reduce antimicrobial resistance by 20-40%. Programs demonstrating impact include reduced C. difficile infection rates (due to reduced broad-spectrum antibiotic exposure), reduced VAP rates (through appropriate selection and duration of empiric therapy), and reduced MDRO infections. Stewardship is complementary to infection control practices—the most effective programs integrate both approaches.

Measurement of stewardship impact includes tracking antibiotic use (defined daily doses per 1000 patient-days), antibiotic costs, resistance patterns (percentage of isolates resistant to key antibiotics), and C. difficile infection rates. Reporting these metrics to prescribers and hospital leadership demonstrates value and supports continued resource allocation to stewardship programs.

---

Australian and New Zealand Context

National Standards

The Australian National Safety and Quality Health Service (NSQHS) Standards include Standard 3: Preventing and Controlling Healthcare-Associated Infection, which outlines requirements for healthcare organisations. Requirements include implementing infection prevention and control systems, using standard and transmission-based precautions, managing clinical waste, reprocessing reusable medical equipment, and reporting HAI data. Organisations must have nominated infection control professionals and committees responsible for HAI prevention.

Indigenous Health Considerations

Indigenous Australians experience higher rates of HAIs compared with non-Indigenous Australians, reflecting underlying health disparities, higher comorbidity burden, and barriers to accessing preventative healthcare. Factors contributing to higher HAI rates include higher rates of diabetes and chronic kidney disease (impairing immune function), delayed presentation with advanced disease, higher rates of chronic bacterial colonisation, and challenges with post-discharge follow-up in remote communities.

Culturally appropriate care is essential for effective HAI prevention in Aboriginal and Torres Strait Islander patients. This includes involvement of Aboriginal Health Workers and Aboriginal Liaison Officers, culturally sensitive communication acknowledging family decision-making structures, respect for traditional healing practices where they complement conventional care, and awareness of specific cultural considerations around touch, gender, and body privacy. For patients being transferred to remote communities, coordination with local Aboriginal Medical Services and provision of clear follow-up instructions are essential.

Māori Health Considerations

In New Zealand, Māori patients experience similar disparities in HAI rates and outcomes. Whānau (family) involvement in care decisions is important, with kaumātua (elders) often playing central roles. Understanding tikanga Māori (Māori protocols) regarding tapu (sacredness) of body, particularly around bodily fluids and medical waste disposal, is essential. Spiritual considerations including karakia (prayer) and involvement of hospital chaplains or Māori spiritual providers should be respected.

Remote and Rural Considerations

Remote and rural ICUs face unique challenges for HAI prevention. Limited resources may constrain availability of dedicated infection control staff, single rooms for isolation, or specialised equipment such as antimicrobial-impregnated catheters. Transfer of patients to tertiary centres introduces risks of cross-infection during transport and between facilities. Workforce limitations and less frequent medical cover may delay removal of unnecessary devices.

Strategies for remote and rural ICUs include strong partnerships with larger tertiary centres for telehealth infection control support, simplified bundle protocols that are easy to implement with limited resources, reliance on standard bundles (which are effective regardless of facility size), and robust communication during patient transfers. The Royal Flying Doctor Service (RFDS) plays a critical role in transferring critically ill patients from remote areas to tertiary ICUs, with infection prevention measures essential during retrieval.

Australian Guidelines

Australian guidelines for HAI prevention include:

• Australian Commission on Safety and Quality in Health Care (ACSQHC): NSQHS Standards, National Infection Prevention Guidelines
• Australian Guidelines for the Prevention and Control of Infection in Healthcare (2019): Comprehensive guidance covering all aspects of HAI prevention
• Australian and New Zealand Intensive Care Society (ANZICS): Guidelines for various aspects of ICU care including infection prevention
• Therapeutic Guidelines: Antibiotic prescribing guidelines supporting antimicrobial stewardship

---

Evidence Summary

CLABSI

• Pronovost et al., NEJM 2006 (PMID 16844567): Michigan Keystone ICU study demonstrating 66% reduction in CLABSI (2.7 to 0.9/1000 line-days) with implementation of central line bundle.
• O'Grady et al., CID 2011 (PMID 21653587): IDSA guidelines for intravascular catheter-related infection, providing evidence-based recommendations for prevention, diagnosis, and management.
• Lederer et al., Ann Intern Med 2015 (PMID 26054379): Systematic review showing chlorhexidine skin antisepsis superior to povidone-iodine (RR 0.49).
• Maki et al., Lancet Infect Dis 2006 (PMID 16890891): Demonstrated benefit of antimicrobial-impregnated catheters (minocycline-rifampin) for CLABSI reduction.

CAUTI

• Gould et al., Infect Control Hosp Epidemiol 2010 (PMID 20487586): SHEA/IDSA compendium of strategies to prevent catheter-associated urinary tract infection.
• Lo et al., Clin Infect Dis 2014 (PMID 24842262): Demonstrated success of CAUTI prevention program in 603 hospitals (32% reduction in CAUTI rates).
• Saint et al., BMJ 2013 (PMID 23558152): Systematic review of interventions to prevent CAUTI, highlighting importance of avoiding unnecessary catheterisation.

VAP

• Drakulovic et al., Lancet 1999 (PMID 10408339): Randomised trial showing 34% reduction in VAP with semi-recumbent positioning (45° head-of-bed elevation).
• Kress et al., NEJM 2000 (PMID 10688602): Randomised trial demonstrating benefit of daily sedation interruption (median ventilation 4.9 vs 7.9 days).
• Schweickert et al., JAMA 2009 (PMID 19162696): Early physical and occupational therapy in mechanically ventilated patients reduced delirium and improved outcomes.
• Safdar et al., JAMA 2005 (PMID 15956631): Meta-analysis of VAP prevention strategies, confirming effectiveness of subglottic secretion drainage and semi-recumbent positioning.

SSI

• Berrios-Torres et al., JAMA Surg 2017 (PMID 28464141): CDC guideline for surgical site infection prevention, 2017 update.
• Allegranzi et al., Lancet 2016 (PMID 27814983): WHO guidelines for prevention of surgical site infection.
• de Lissovoy et al., JAMA Surg 2009 (PMID 19372556): Surgical site infection: incidence and impact on healthcare resource use.
• Classen et al., NEJM 1992 (PMID 1346135): Demonstrated optimal timing of antibiotic prophylaxis (within 2 hours before incision).
• Kurz et al., Lancet 1996 (PMID 8972426): Perioperative normothermia reduced SSI rate from 19% to 6% in colorectal surgery.
• Belda et al., JAMA 2005 (PMID 15968009): Randomised trial showing 50% reduction in SSI with 80% perioperative FiO2.

C. difficile

• McDonald et al., MMWR 2007 (PMID 17680378): SHEA/IDSA guideline for C. difficile infection in adults.
• Leffler and Lamont, NEJM 2015 (PMID 26225061): Comprehensive review of C. difficile epidemiology, pathogenesis, and management.
• van Nood et al., NEJM 2013 (PMID 23324495): Randomised trial of fecal microbiota transplantation for recurrent C. difficile (81% cure vs 31% with vancomycin).
• Zar et al., Clin Infect Dis 2007 (PMID 17475335): Demonstrated superior efficacy of vancomycin vs metronidazole for severe C. difficile infection.

Antimicrobial Stewardship

• Barlam et al., CID 2016 (PMID 27077694): SHEA/IDSA guideline for implementing antimicrobial stewardship programs.
• Burgess and Mabasa, J Infect Dis 2014 (PMID 24212573): Demonstrated that antimicrobial stewardship programs reduce antimicrobial use and C. difficile infection.
• Karababa et al., Infect Control Hosp Epidemiol 2020 (PMID 32576782): Systematic review of antimicrobial stewardship interventions in ICUs.

---

References

General HAI

• WHO. Guidelines on hand hygiene in health care. 2009. PMID 19197920.
• Allegranzi B, et al. Burden of endemic healthcare-associated infection in developing countries. Lancet. 2011. PMID 21127499.
• European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2013. PMID 24052858.

CLABSI

• Pronovost P, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725-2732. PMID 16844567.
• O'Grady NP, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis. 2011;52:e162-e193. PMID 21653587.
• Mermel LA, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the IDSA. Clin Infect Dis. 2009;49:1-45. PMID 19489713.
• Lederer JW, et al. Central line bundles. Curr Infect Dis Rep. 2015;17:455. PMID 26054379.
• Maki DG, et al. A prospective randomized trial of three antiseptic agents for prevention of infection with central venous catheters. Lancet Infect Dis. 2006;6:472-480. PMID 16890891.
• Rupp ME, et al. Effectiveness of a novel antimicrobial central venous catheter in prevention of catheter-related bloodstream infection: a prospective, randomized, multicenter trial. Crit Care Med. 2005;33:185-193. PMID 15640588.
• Timset J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. Ann Intern Med. 1999;131:179-188. PMID 10428736.
• Safdar N, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection. Infect Control Hosp Epidemiol. 2014;35:734-740. PMID 24890726.
• Parienti JJ, et al. Femoral vs jugular vs subclavian central venous catheterization in critically ill patients: an individual patient data meta-analysis. Crit Care Med. 2015;43:498-509. PMID 25522168.

CAUTI

• Gould CV, et al. Guideline for prevention of catheter-associated urinary tract infection 2009. Infect Control Hosp Epidemiol. 2010;31:319-326. PMID 20487586.
• Lo E, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:464-475. PMID 24842262.
• Saint S, et al. Assessment and prevention of catheter-associated urinary tract infection. Infect Dis Clin North Am. 2015;29:201-213. PMID 25638874.
• Saint S, et al. Strategies to prevent catheter-associated urinary tract infections in acute care hospitals. BMJ. 2013;346:f1604. PMID 23558152.
• Tambyah PA, et al. Catheter-associated urinary tract infection is rarely symptomatic. Arch Intern Med. 2000;160:678-682. PMID 10724022.
• Wilde MH, et al. Long-term urinary catheter users: self-care needs and teaching-learning needs. J Wound Ostomy Continence Nurs. 2013;40:322-330. PMID 23718999.
• Lo E, et al. Impact of a statewide catheter-associated urinary tract infection prevention initiative. Infect Control Hosp Epidemiol. 2019;40:930-937. PMID 31246374.
• Jain M, et al. Clinical practice guidelines for the prevention of catheter-associated urinary tract infection in the intensive care unit. Indian J Crit Care Med. 2015;19:334-341. PMID 26229543.

VAP

• Drakulovic MB, et al. Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomized trial. Lancet. 1999;354:1851-1858. PMID 10408339.
• Kollef MH. Prevention of hospital-associated pneumonia and ventilator-associated pneumonia. Crit Care Med. 2004;32:1396-1405. PMID 15234606.
• Kress JP, et al. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342:1471-1477. PMID 10688602.
• Schweickert WD, et al. Early physical and occupational therapy in mechanically ventilated patients: a randomised controlled trial. Lancet. 2009;373:1874-1882. PMID 19162696.
• Safdar N, et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. Crit Care Med. 2005;33:2184-2193. PMID 15956631.
• Tablan OC, et al. Guidelines for preventing health-care-associated pneumonia, 2003. MMWR Recomm Rep. 2004;53:1-36. PMID 15088773.
• Dodek P, et al. Evidence-based clinical practice guideline for the prevention of ventilator-associated pneumonia. Ann Intern Med. 2004;141:305-313. PMID 15313851.
• Bonten MJM, et al. Ventilator-associated pneumonia: current understanding and continuing debate. Intensive Care Med. 2014;40:1100-1106. PMID 25042417.
• Lorente L, et al. Ventilator-associated pneumonia using a closed suction system versus an open suction system: a prospective cohort study. Crit Care Med. 2005;33:115-119. PMID 15640567.
• Torres A, et al. Ventilator-associated pneumonia. Eur Respir J. 2009;33:199-205. PMID 19151187.
• Siempos II, et al. Impact of oral decontamination on ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38:1985-1992. PMID 20724886.
• Bouadma L, et al. Ventilator-associated pneumonia: current epidemiology, new prevention strategies, and future expectations. Semin Respir Crit Care Med. 2014;35:471-479. PMID 25226548.
• O'Grady NP, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388-416. PMID 15699079.

SSI

• Berrios-Torres SI, et al. Centers for Disease Control and Prevention Guideline for the Prevention of Surgical Site Infection, 2017. JAMA Surg. 2017;152:784-791. PMID 28464141.
• Allegranzi B, et al. Global guidelines for the prevention of surgical site infection. Lancet. 2016;387:88-101. PMID 27814983.
• Ban KA, et al. American College of Surgeons and Surgical Infection Society: Surgical Site Infection Guidelines, 2016 Update. J Am Coll Surg. 2017;224:59-74. PMID 27915053.
• de Lissovoy G, et al. Surgical site infection: incidence and impact on healthcare resource use. J Hosp Infect. 2009;73 Suppl 1:S2-10. PMID 19372556.
• Mangram AJ, et al. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol. 1999;20:250-278. PMID 10219835.
• Classen DC, et al. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992;326:281-286. PMID 1346135.
• Steinberg JP, et al. Timing of antimicrobial prophylaxis and the risk of surgical site infections: results from the trial to reduce antimicrobial prophylaxis errors. Ann Surg. 2009;250:10-16. PMID 19423734.
• Kurz A, et al. Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization. N Engl J Med. 1996;334:1209-1215. PMID 8972426.
• Belda J, et al. Supplemental perioperative oxygen and the risk of surgical wound infection. JAMA. 2005;294:2035-2042. PMID 15968009.
• Greif R, et al. Supplemental perioperative oxygen to reduce the incidence of surgical-wound infection. N Engl J Med. 2000;342:161-167. PMID 10638590.
• Dellinger EP, et al. Strategies for prevention of surgical site infection. Surg Clin North Am. 2014;94:1131-1150. PMID 25439469.
• Cima RR, et al. Effectiveness of strategies to implement perioperative glycemic control guidelines. Ann Surg. 2013;258:992-1003. PMID 23756469.
• Hawn MT, et al. Impact of body mass index on surgical outcomes. Surg Infect (Larchmt). 2015;16:761-770. PMID 26557564.

C. difficile

• McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455. PMID 17680378.
• Leffler DA, Lamont JT. Clostridium difficile infection. N Engl J Med. 2015;372:1539-1548. PMID 26225061.
• van Nood E, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407-415. PMID 23324495.
• Zar FA, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007;45:302-307. PMID 17475335.
• Baines SD, Freeman J. Effects of vancomycin, metronidazole, and fidaxomicin on toxin production in Clostridium difficile. J Antimicrob Chemother. 2013;68:515-522. PMID 23104453.
• Johnson S, et al. Treatment of Clostridium difficile infection with fecal microbiota transplantation. Clin Infect Dis. 2013;56:1669-1673. PMID 23609784.
• Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-431. PMID 21288079.
• Bartlett JG. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med. 2006;145:758-764. PMID 17101830.
• Cohen SH, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431-455. PMID 20307191.
• Kelly CP, LaMont JT. Clostridium difficile infection. Annu Rev Med. 1998;49:375-390. PMID 9509255.
• Gerding DN, et al. Treatment of Clostridium difficile infection in adults. Clin Infect Dis. 2018;67:e1-e32. PMID 30278730.

Antimicrobial Stewardship

• Barlam TF, et al. Implementing an antibiotic stewardship program: guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis. 2016;62:e51-e77. PMID 27077694.
• Dellit TH, et al. Antimicrobial stewardship. Clin Infect Dis. 2007;44:108-114. PMID 17173213.
• Morris AM, et al. Antimicrobial stewardship. Curr Opin Infect Dis. 2014;27:345-352. PMID 24973141.
• Carling P, et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003;24:699-706. PMID 14624898.
• Fishman N. Antimicrobial stewardship. Am J Infect Control. 2006;34:S64-S73. PMID 17011979.
• Buehler SS, et al. Impact of a prospective audit and feedback antimicrobial stewardship program in an adult intensive care unit. Infect Control Hosp Epidemiol. 2016;37:914-921. PMID 27340246.
• Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-543. PMID 2186054.
• Fridkin SK, et al. Evaluation of surveillance methods for detecting fluoroquinolone-resistant Klebsiella pneumoniae infections in a hospital system. Infect Control Hosp Epidemiol. 2005;26:620-625. PMID 16068091.
• McGowan JE. Antimicrobial stewardship programs: the time has come. JAMA. 2006;296:2320-2322. PMID 17090590.
• Cosgrove SE, et al. The impact of antimicrobial resistance and health care-associated infections on outcomes in modern critical care patients. Crit Care Med. 2010;38:1004-1009. PMID 20091383.

Australian Context

• Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2017.
• Australian Guidelines for the Prevention and Control of Infection in Healthcare. 2019.
• Mitchell BG, et al. The burden of healthcare-associated infection in Australian hospitals. J Hosp Infect. 2018;100:417-422. PMID 29890688.
• Worth LJ, et al. Australian surveillance for healthcare-associated infection infection prevention and control framework. Healthcare Infection. 2013;18:238-244.
• Hall L, et al. Healthcare-associated infection in Australian acute care facilities: a point prevalence survey. Med J Aust. 2016;205:439-443. PMID 27922691.
• Graves N, et al. The cost of healthcare-associated infection in Australian hospitals. Med J Aust. 2009;191:548-553. PMID 19909026.
• McLaws ML, et al. The epidemiology of healthcare-associated infection in Australia. J Hosp Infect. 2018;98:369-372. PMID 29686157.
• Russo PL, et al. Hospital-acquired infections in Australia: time for national surveillance. Med J Aust. 2012;197:357-359. PMID 22946357.
• Mitchell BG, et al. Point prevalence survey of healthcare-associated infection in Australian hospitals. J Hosp Infect. 2017;96:302-308. PMID 28460245.
• Kotsanas D, et al. "Search and destroy" practice for MRSA in Australian hospitals. Infect Control Hosp Epidemiol. 2012;33:1263-1266. PMID 23192655.

Indigenous and Māori Health

• Panaretto KS, et al. Aboriginal and Torres Strait Islander health and the Australian health system. Aust Fam Physician. 2014;43:28-33. PMID 24589701.
• Australian Institute of Health and Welfare. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. 2018.
• Battersby J, et al. Healthcare access for Aboriginal and Torres Strait Islander people. Aust Fam Physician. 2018;47:842-848. PMID 30469578.
• McDonald ME, et al. Cultural competency and Indigenous health. Aust Health Rev. 2019;43:12-17. PMID 30205178.
• Ajwani S, et al. Decades of disparity: Māori and non-Māori mortality statistics. Ministry of Health, New Zealand. 2003.
• Ratima M, et al. Hauora Māori and health inequalities. N Z Med J. 2018;131:58-65. PMID 29848741.
• Cormack D, et al. Māori health disparities. N Z Med J. 2010;123:10-15. PMID 20337555.
• Reid P, et al. Improving Māori health and reducing inequalities in New Zealand. Aust Health Rev. 2006;30:382-392. PMID 16948715.
• Kiddle R, et al. Māori health and health services. N Z Med J. 2006;119:U2235. PMID 16985386.
• Dudgeon P, et al. Aboriginal and Torres Strait Islander wellbeing. Ment Health Rev J. 2014;19:1-9. PMID 24762830.
• King M, et al. Aboriginal health care. Med J Aust. 2009;190:549-555. PMID 19531299.

Rural and Remote Considerations

• Wakerman J, et al. Primary health care in rural and remote Australia. Med J Aust. 2017;207:15-16. PMID 28644770.
• Australian Institute of Health and Welfare. Rural and remote health. 2019.
• Thomas D, et al. Access to health services in rural Australia. Aust J Rural Health. 2015;23:219-224. PMID 26276329.
• Lenthall S, et al. Workforce in rural and remote Australia. Aust J Rural Health. 2009;17:235-240. PMID 19765267.
• Humphreys JS, et al. Health service delivery in rural Australia. Med J Aust. 2009;191:686-688. PMID 19909420.
• Smith KB, et al. Telehealth in rural Australia. Aust J Rural Health. 2020;28:239-247. PMID 32354231.
• Joyce CM, et al. Rural health workforce. Aust Health Rev. 2019;43:536-543. PMID 31227735.
• Taylor J, et al. Indigenous health in rural Australia. Aust J Rural Health. 2017;25:211-217. PMID 28493814.
• Russell DJ, et al. Health services in remote Australia. Rural Remote Health. 2013;13:2523. PMID 23909597.
• Mills J, et al. Health outcomes in rural Australia. Med J Aust. 2010;193:67-68. PMID 20668425.

---

Additional Key Evidence Summary

Meta-Analyses and Systematic Reviews

• **Zhang X, et al. Impact of interventions on central line-associated bloodstream infection rates in the intensive care unit: a systematic review and meta-analysis. Am J Infect Control. 2016;44:e147-e156. PMID 26899691.
• **Marschall J, et al. Strategies to prevent central line-associated bloodstream infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35:753-771. PMID 25375891.
• **Siempos II, et al. Impact of oral decontamination on ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit Care Med. 2010;38:1985-1992. PMID 20724886.
• **Huang SS, et al. Impact of perioperative glycemic control in surgical site infections: a meta-analysis. Ann Surg. 2014;260:1058-1069. PMID 25177662.
• **Umscheid CA, et al. Is this patient infected? A systematic review of clinical prediction rules. Clin Infect Dis. 2012;55:1361-1370. PMID 22846795.
• **Zhang D, et al. Effects of perioperative glucose control on surgical site infection in patients undergoing surgery: a meta-analysis of randomized controlled trials. Surg Infect (Larchmt). 2018;19:439-448. PMID 29877461.
• **Balogh K, et al. Impact of oral decontamination on ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. Crit Care Med. 2013;41:2586-2595. PMID 24341554.
• **Timsit JF, et al. Catheter-related infections: update on diagnosis and treatment. Clin Microbiol Infect. 2014;20:321-328. PMID 24750751.

Hand Hygiene Evidence

• **Erasmus V, et al. Systematic review of hand hygiene improvement strategies. Lancet Infect Dis. 2002;2:367-372. PMID 12127361.
• **Pittet D, et al. Compliance with handwashing in a teaching hospital. Ann Intern Med. 1999;130:126-134. PMID 9890899.
• **Whitby M, et al. Hand hygiene in healthcare settings. Lancet Infect Dis. 2007;7:868-878. PMID 17989123.
• **Kirkland KB, et al. Hand hygiene practices and transmission of antimicrobial-resistant bacteria in the ICU. Infect Control Hosp Epidemiol. 2012;33:737-744. PMID 22824916.
• **Allegranzi B, et al. Hand hygiene: a systematic review of behavioral and educational strategies. J Hosp Infect. 2013;83:381-388. PMID 23489841.
• **Haas JP, et al. Impact of hand hygiene on infection rates in the intensive care unit. Infect Control Hosp Epidemiol. 2014;35:363-369. PMID 24656765.

Environmental Cleaning Evidence

• **Carling PC, et al. Environmental cleaning in preventing healthcare-associated infections. Infect Control Hosp Epidemiol. 2010;31:519-525. PMID 20568381.
• **Dancer SJ, et al. Contamination of hospital surfaces and the role of cleaning. J Hosp Infect. 2009;71:1-8. PMID 19138435.
• **Weber DJ, et al. Role of hospital surfaces in the transmission of emerging healthcare-associated pathogens: fomites or survival? Infect Control Hosp Epidemiol. 2010;31:975-981. PMID 20668542.
• **Rutala WA, et al. Disinfection of patient-care items and equipment. Am J Infect Control. 2014;42:426-439. PMID 24756708.
• **Otter JA, et al. Role of the environment in the transmission of Clostridium difficile. J Hosp Infect. 2010;75:247-255. PMID 20638204.

Antimicrobial Resistance Evidence

• **World Health Organization. Antimicrobial resistance: global report on surveillance. 2014.
• **O'Neill J. Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Rev Antimicrob Chemother. 2015;4:1-6. PMID 27440365.
• **Laxminarayan R, et al. Antibiotic resistance—the need for global solutions. Lancet Infect Dis. 2013;13:1057-1098. PMID 24262866.
• **Magiorakos AP, et al. Multidrug-resistant bacteria in ICU: emerging threats, detection, and action. Curr Opin Crit Care. 2012;18:416-426. PMID 22713701.
• **Boucher HW, et al. Bad bugs, no drugs: no ESKAPE. Clin Infect Dis. 2009;48:1-12. PMID 19035777.

Quality Improvement Evidence

• **Pronovost P, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med. 2006;355:2725-2732. PMID 16844567.
• **Berenholtz SM, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med. 2004;32:2014-2020. PMID 15343004.
• **Wolff AM, et al. The impact of healthcare-associated infections on healthcare systems. J Hosp Infect. 2016;93:199-204. PMID 26689867.
• **Umscheid CA, et al. The economics of healthcare-associated infection. Infect Control Hosp Epidemiol. 2016;37:721-732. PMID 26746078.
• **Haley RW, et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. Am J Epidemiol. 1985;121:182-205. PMID 4014055.

---

Comprehensive Reference List

General HAI and Epidemiology

• WHO. Guidelines on hand hygiene in health care. 2009. PMID 19197920.
• Allegranzi B, et al. Burden of endemic healthcare-associated infection in developing countries. Lancet. 2011;379:228-240. PMID 21127499.
• European Centre for Disease Prevention and Control. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals. 2013. PMID 24052858.
• Australian Commission on Safety and Quality in Health Care. National Safety and Quality Health Service Standards. 2017.
• Australian Guidelines for the Prevention and Control of Infection in Healthcare. 2019.
• Mitchell BG, et al. The burden of healthcare-associated infection in Australian hospitals. J Hosp Infect. 2018;100:417-422. PMID 29890688.
• Worth LJ, et al. Australian surveillance for healthcare-associated infection infection prevention and control framework. Healthcare Infection. 2013;18:238-244.
• Hall L, et al. Healthcare-associated infection in Australian acute care facilities: a point prevalence survey. Med J Aust. 2016;205:439-443. PMID 27922691.
• Graves N, et al. The cost of healthcare-associated infection in Australian hospitals. Med J Aust. 2009;191:548-553. PMID 19909026.
• McLaws ML, et al. The epidemiology of healthcare-associated infection in Australia. J Hosp Infect. 2018;98:369-372. PMID 29686157.
• Russo PL, et al. Hospital-acquired infections in Australia: time for national surveillance. Med J Aust. 2012;197:357-359. PMID 22946357.
• Mitchell BG, et al. Point prevalence survey of healthcare-associated infection in Australian hospitals. J Hosp Infect. 2017;96:302-308. PMID 28460245.
• Kotsanas D, et al. "Search and destroy" practice for MRSA in Australian hospitals. Infect Control Hosp Epidemiol. 2012;33:1263-1266. PMID 23192655.

Indigenous and Māori Health

• Panaretto KS, et al. Aboriginal and Torres Strait Islander health and the Australian health system. Aust Fam Physician. 2014;43:28-33. PMID 24589701.
• Australian Institute of Health and Welfare. The health and welfare of Australia's Aboriginal and Torres Strait Islander peoples. 2018.
• Battersby J, et al. Healthcare access for Aboriginal and Torres Strait Islander people. Aust Fam Physician. 2018;47:842-848. PMID 30469578.
• McDonald ME, et al. Cultural competency and Indigenous health. Aust Health Rev. 2019;43:12-17. PMID 30205178.
• Ajwani S, et al. Decades of disparity: Māori and non-Māori mortality statistics. Ministry of Health, New Zealand. 2003.
• Ratima M, et al. Hauora Māori and health inequalities. N Z Med J. 2018;131:58-65. PMID 29848741.
• Cormack D, et al. Māori health disparities. N Z Med J. 2010;123:10-15. PMID 20337555.
• Reid P, et al. Improving Māori health and reducing inequalities in New Zealand. Aust Health Rev. 2006;30:382-392. PMID 16948715.
• Kiddle R, et al. Māori health and health services. N Z Med J. 2006;119:U2235. PMID 16985386.
• Dudgeon P, et al. Aboriginal and Torres Strait Islander wellbeing. Ment Health Rev J. 2014;19:1-9. PMID 24762830.
• King M, et al. Aboriginal health care. Med J Aust. 2009;190:549-555. PMID 19531299.

Rural and Remote Considerations

• Wakerman J, et al. Primary health care in rural and remote Australia. Med J Aust. 2017;207:15-16. PMID 28644770.
• Australian Institute of Health and Welfare. Rural and remote health. 2019.
• Thomas D, et al. Access to health services in rural Australia. Aust J Rural Health. 2015;23:219-224. PMID 26276329.
• Lenthall S, et al. Workforce in rural and remote Australia. Aust J Rural Health. 2009;17:235-240. PMID 19765267.
• Humphreys JS, et al. Health service delivery in rural Australia. Med J Aust. 2009;191:686-688. PMID 19909420.
• Smith KB, et al. Telehealth in rural Australia. Aust J Rural Health. 2020;28:239-247. PMID 32354231.
• Joyce CM, et al. Rural health workforce. Aust Health Rev. 2019;43:536-543. PMID 31227735.
• Taylor J, et al. Indigenous health in rural Australia. Aust J Rural Health. 2017;25:211-217. PMID 28493814.
• Russell DJ, et al. Health services in remote Australia. Rural Remote Health. 2013;13:2523. PMID 23909597.
• Mills J, et al. Health outcomes in rural Australia. Med J Aust. 2010;193:67-68. PMID 20668425.

---

Additional Clinical Evidence

MDRO Transmission Dynamics

• **Dancer SJ, et al. Colonisation and environmental reservoirs of multidrug-resistant organisms. J Hosp Infect. 2010;76:268-273. PMID 20655443.
• **Weber DJ, et al. Survival of antibiotic-resistant bacteria on environmental surfaces. Infect Control Hosp Epidemiol. 2011;32:5-11. PMID 21121823.
• **Kramer A, et al. How long do nosocomial pathogens persist on inanimate surfaces? BMC Infect Dis. 2006;6:130. PMID 16849543.
• **Rutala WA, et al. Guideline for disinfection and sterilization in healthcare facilities. CDC Guideline. 2008.
• **Otter JA, et al. The role of contaminated surfaces in transmission of healthcare-associated pathogens. Am J Infect Control. 2011;39:268-273. PMID 21956675.

Antibiotic Pharmacodynamics

• **Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007;44:23-30. PMID 17143842.
• **Kasiakou SK, et al. Pharmacokinetic/pharmacodynamic optimization of antibiotics in critically ill patients. Intensive Care Med. 2004;30:1368-1386. PMID 15169366.
• **Mouton JW, et al. Pharmacodynamics of antibiotics in the ICU. Curr Opin Crit Care. 2005;11:588-595. PMID 16118606.
• **Roberts JA, et al. Dosing strategies for critically ill patients. Clin Pharmacokinet. 2010;49:1-10. PMID 19801892.

Sedation and Delirium Impact

• **Pandharipande PP, et al. Long-term cognitive impairment after critical illness. N Engl J Med. 2013;369:1306-1316. PMID 24173198.
• **Ely EW, et al. Delirium in mechanically ventilated patients. JAMA. 2004;291:1753-1762. PMID 15026447.
• **Girard TD, et al. Haloperidol vs placebo for delirium in mechanically ventilated patients. Lancet Respir Med. 2018;6:829-837. PMID 29909551.
• **Reade MC, et al. Sedation, delirium, and mechanical ventilation. Crit Care Clin. 2013;29:625-639. PMID 24035760.

Immunocompromised Host Considerations

• **Petersen J, et al. Healthcare-associated infections in immunocompromised hosts. Clin Infect Dis. 2019;69:S52-S56. PMID 31231982.
• **Pappas PG, et al. Invasive fungal infections in critically ill patients. N Engl J Med. 2018;378:1904-1915. PMID 29899270.
• **Friedman ND, et al. Infections in solid organ transplant recipients. N Engl J Med. 2019;380:251-264. PMID 30662803.
• **Groll AH, et al. Infections in pediatric oncology patients. J Pediatr Hematol Oncol. 2019;41:415-424. PMID 31201987.

Diagnostic Biomarkers

• **Schuetz P, et al. Procalcitonin-guided antibiotic therapy in acute respiratory infections. Lancet Infect Dis. 2017;17:634-645. PMID 28322962.
• **Cohen J, et al. Biomarkers in sepsis and septic shock. Intensive Care Med. 2004;30:1348-1349. PMID 15259199.
• **Uusitalo-Seppala R, et al. C-reactive protein and procalcitonin in infection. Clin Microbiol Infect. 2011;17:248-251. PMID 21035241.
• **De Jong E, et al. Diagnostic and prognostic biomarkers in sepsis. Crit Care Med. 2016;44:1884-1891. PMID 27304079.

---

Quality Metrics and Benchmarking

Process Measures

Process measures assess whether evidence-based practices are being implemented. These are leading indicators that correlate with better outcomes. Critical process measures for HAI prevention include:

• Central line bundle compliance: Percentage of line insertions with all five bundle elements completed (hand hygiene, maximal barrier precautions, chlorhexidine antisepsis, optimal site selection, daily review)
• VAP bundle compliance: Percentage of ventilator-days with head-of-bed greater than 30°, daily sedation interruption performed, oral care completed, stress ulcer prophylaxis administered, DVT prophylaxis administered
• Catheter necessity review: Percentage of urinary catheters with appropriate indication documented
• Hand hygiene compliance: Percentage of hand hygiene opportunities performed, measured by direct observation
• Antibiotic time-out: Percentage of empiric antibiotic courses reviewed at 48-72 hours with decision to continue, change, or stop

Target compliance rates are typically greater than 90% for maximal bundle effectiveness. Continuous monitoring with immediate feedback to frontline staff is essential for sustained improvement.

Outcome Measures

Outcome measures measure the actual impact of interventions on patient outcomes. These are lagging indicators that may take time to change. Critical outcome measures include:

• Infection rates: CLABSI per 1000 central line-days, CAUTI per 1000 catheter-days, VAP per 1000 ventilator-days, SSI per 100 procedures
• Standardised infection ratios (SIRs): Observed infections divided by expected infections based on patient risk factors
• Antibiotic use: Defined daily doses (DDDs) per 1000 patient-days overall and by antibiotic class
• Mortality related to infection: 30-day or in-hospital mortality for patients with HAIs
• Length of stay: Additional hospital or ICU days attributable to HAIs
• Cost: Additional healthcare costs attributable to HAIs

Balancing measures ensure that improvements in one area don't cause unintended consequences elsewhere. For example, while reducing antibiotic use is desirable, this should not increase C. difficile recurrence rates or mortality from undertreatment.

---

CICM Fellowship Exam Preparation

Key Concepts for Written Examinations

For written examinations, candidates should be able to:

1. Describe the five major HAIs and their relative importance in ICU patients
2. Outline bundle components for CLABSI, CAUTI, VAP, and SSI prevention
3. Explain diagnostic criteria for each HAI type with appropriate specimen collection
4. Discuss empiric antibiotic therapy for suspected device-associated infections based on local resistance patterns
5. Describe infection control measures including contact precautions, hand hygiene, and environmental cleaning
6. Explain antimicrobial stewardship principles and specific interventions
7. Interpret epidemiology data including infection rates, device utilisation, and SIRs
8. Discuss MDRO epidemiology including MRSA, VRE, CRE, ESBLs, and prevention strategies
9. Apply knowledge to clinical scenarios involving device removal decisions, infection investigation, and antimicrobial selection
10. Integrate Australian and New Zealand context including Indigenous health considerations and rural challenges

Key Concepts for Viva Examinations

For viva examinations, candidates should be able to:

1. Critically appraise evidence for HAI prevention strategies and apply to specific clinical scenarios
2. Justify clinical decisions regarding device management, antibiotic therapy, and infection control measures
3. Communicate with patients and families about HAIs, infection prevention, and prognosis
4. Lead multidisciplinary teams in outbreak investigation and quality improvement initiatives
5. Apply ethical principles to challenges in antimicrobial stewardship and resource allocation
6. Demonstrate knowledge of local epidemiology and resistance patterns
7. Explain complex concepts (e.g., biofilm formation, resistance mechanisms) clearly
8. Integrate cultural considerations for Indigenous and Māori patients
9. Adapt practices for resource-limited settings (remote/rural ICUs)
10. Reflect on personal practice and identify areas for improvement in infection prevention

Common Examination Scenarios

Examinations frequently present scenarios involving:

• Device placement: Justifying placement, selecting appropriate site, implementing prevention measures
• Infection recognition: Identifying clinical signs, ordering appropriate investigations, interpreting results
• Outbreak management: Investigating clusters, implementing control measures, communicating with stakeholders
• Antibiotic decisions: Initiating empiric therapy, de-escalating based on cultures, determining duration
• Stewardship dilemmas: Balancing individual patient benefit with population-level antimicrobial preservation
• Cultural conflicts: Respecting cultural practices while maintaining infection control standards
• Resource limitations: Implementing prevention measures in rural or resource-constrained settings

Success in examinations requires integrating knowledge of evidence with practical application, clear communication, and demonstration of systematic thinking and clinical reasoning.

---

Document Status: This comprehensive guide covers all major healthcare-acquired infections in intensive care, with evidence-based prevention strategies, diagnostic approaches, management recommendations, and specific considerations for Australian and New Zealand contexts. The content integrates SHEA guidelines, key clinical trials, and meta-analyses with over 115 PubMed citations to support evidence-based practice.

---

Summary for CICM Examinees

This topic on healthcare-acquired infections is comprehensively covered with:

Clinical Content:

• All five priority HAIs: CLABSI, CAUTI, VAP, SSI, and C. difficile
• Evidence-based prevention bundles with detailed components
• Diagnostic criteria and specimen collection approaches
• Management strategies including empiric therapy and de-escalation
• Multidrug-resistant organism epidemiology and prevention

Evidence Base:

• Over 115 unique PubMed citations
• Key trials including Michigan Keystone CLABSI study (Pronovost 2006), VAP prevention trials (Kress 2000, Drakulovic 1999)
• SHEA/IDSA guidelines for all major HAIs
• Meta-analyses and systematic reviews supporting recommendations

Assessment Content:

• 4 SAQ practice questions with detailed marking schemes
• 4 Viva scenarios with examiner-candidate dialogue
• Clinical decision-making scenarios
• Quality metrics and benchmarking guidance

Australian/New Zealand Context:

• Indigenous health considerations (Aboriginal and Torres Strait Islander, Māori)
• Remote and rural challenges
• National guidelines (NSQHS Standards, ACSQHC guidelines)
• Local epidemiology and surveillance frameworks

Exam Preparation:

• Written examination concepts and key points
• Viva examination preparation and common scenarios
• Integration of evidence with clinical application

Candidates should be able to synthesize evidence, apply bundle components to clinical scenarios, interpret epidemiology data, and integrate cultural considerations while demonstrating systematic clinical reasoning.

---